

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12N 15/12, 15/62	A1	(11) International Publication Number: WO 94/10308 (43) International Publication Date: 11 May 1994 (11.05.94)
(21) International Application Number: PCT/US93/10034 (22) International Filing Date: 20 October 1993 (20.10.93) (30) Priority data: 07/969,703 23 October 1992 (23.10.92) US 08/107,353 13 August 1993 (13.08.93) US (71) Applicant: IMMUNEX CORPORATION [US/US]; 51 University Street, Seattle, WA 98101 (US). (72) Inventors: SPRIGGS, Melanie, K. ; 2256 12th Avenue West, Seattle, WA 98119 (US). SRINIVASAN, Subhashini ; 11325 N.E. 129th Street, Kirkland, WA 98034 (US). (74) Agent: PERKINS, Patricia, Anne; Immunex Corporation, 51 University Street, Seattle, WA 98101 (US).		(81) Designated States: AU, CA, JP, NZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: METHODS OF PREPARING SOLUBLE, OLIGOMERIC PROTEINS (57) Abstract There is disclosed a method of preparing a soluble mammalian protein by culturing a host cell transformed or transfected with an expression vector encoding a fusion protein comprising a leucine zipper domain and a heterologous mammalian protein.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo			SE	Sweden
CH	Switzerland	KR	Republic of Korea	SI	Slovenia
CI	Côte d'Ivoire	KZ	Kazakhstan	SK	Slovakia
CM	Cameroon	LJ	Liechtenstein	SN	Senegal
CN	China	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
CZ	Czech Republic	LV	Latvia	TJ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Viet Nam
GA	Gabon				

TITLE**METHODS OF PREPARING SOLUBLE, OLIGOMERIC PROTEINS****TECHNICAL FIELD OF THE INVENTION**

The present invention relates to a method of preparing soluble oligomeric proteins using recombinant DNA technology.

BACKGROUND OF THE INVENTION

10 The biological activity of proteins is dependent upon proper tertiary and quaternary structure, or conformation. Many proteins exist as oligomers (structures comprised of two or more polypeptide chains) in their native form. Such oligomers are often stabilized by non-covalent interactions, and are thus dependent on proper tertiary structure of the individual peptides. Expression of a recombinant protein in biologically
15 active form, exhibiting the proper tertiary and quaternary structure, by host cells which do not normally express a native form of the protein, frequently presents a significant challenge. Of particular interest in recombinant protein technology is expression of proteins that are membrane-bound in the biologically active form, as soluble proteins. Soluble proteins are useful as therapeutic agents, and in other applications requiring
20 large quantities of highly purified proteins.

 Soluble forms of transmembrane proteins have been prepared by deleting the transmembrane and intracytoplasmic domains, and adding an appropriate signal peptide to enable secretion of the soluble form of the protein (Smith et al., *Science* 238:1704, 1987; Treiger et al., *J. Immunol.* 136:4099, 1986). Some soluble proteins have been
25 expressed as fusion proteins in which the extracellular domain of the membrane protein is joined to an immunoglobulin heavy chain constant region (Fanslow et al., *J. Immunol.* 149:65, 1992; Noelle et al., *Proc. Natl. Acad. Sci. U.S.A.* 89:6550, 1992), or with the extracellular domain of the murine T lymphocyte antigen CD8 (Hollenbaugh et al., *EMBO J.* 11:4313, 1992). However, such soluble proteins may not be
30 biologically active due to improper tertiary and/or quaternary structure. Some soluble forms of transmembrane proteins may be biologically active, but poorly expressed, or unstable under the conditions of expression or purification, due to changes in structure as a result of deletion of a portion or portions of the protein.

 Leucine zipper is a term that is used to refer to a repetitive heptad motif
35 containing four to five leucine residues present as a conserved domain in several proteins. Leucine zippers fold as short, parallel coiled coils, and are believed to be responsible for oligomerization of the proteins of which they form a domain. Sequences derived from the *fos* and *jun* leucine zippers have been used in the formation

of bispecific antibodies by expression of DNA encoding the V_L and V_H regions of antibodies as fusion proteins with the leucine zipper sequences: (Kostelny et al., *J. Immunol.* 148:1547, 1992) Leucine zipper sequences have also been used to replace the dimerization domain of λ repressor, a soluble DNA-binding protein of bacteriophage λ (Hu et al., *Science* 250:1400, 1990), and in the preparation of a dimeric form of MalE, a maltose binding protein of *E. coli* that is exported into the periplasmic space (Blondel and Bedouelle, *Protein Engineering* 4:457, 1991).

There is a need in the art to develop methods of expressing biologically active, recombinant, oligomeric proteins, particularly soluble proteins that are membrane-bound in their biologically active configuration.

SUMMARY OF THE INVENTION

The present invention relates to a method of preparing a soluble, oligomeric mammalian protein by culturing a host cell transformed or transfected with an expression vector encoding a fusion protein comprising a leucine zipper domain and a heterologous mammalian protein. In one embodiment, the heterologous mammalian protein comprises an extracellular domain of a mammalian transmembrane protein; the resulting fusion protein forms an oligomer. In another embodiment, the heterologous mammalian protein comprises a soluble protein such as a cytokine; the resulting fusion protein forms an oligomer. In another embodiment, the leucine zipper domain is removed from the fusion protein, by cleavage with a specific proteolytic enzyme. In another embodiment, a hetero-oligomeric protein is prepared by utilizing leucine zipper domains that preferentially form hetero-oligomers.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A illustrates the ability of soluble, oligomeric human CD40-L comprising a leucine zipper domain to stimulate the proliferation of human tonsillar B cells; Figure 1B illustrates the ability of soluble, oligomeric human CD40-L comprising a leucine zipper domain to stimulate the proliferation of human peripheral blood B cells.

Figure 2 illustrates the inhibition of binding of CD27.Fc to MP.1 cells, which express CD27-L, by a soluble form of CD27-L, sCD27L-3, that comprises a leucine zipper domain.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a method of preparing a soluble mammalian protein by culturing a host cell transformed or transfected with an expression vector encoding a fusion protein comprising a leucine zipper domain and a heterologous mammalian protein. In one embodiment, the heterologous mammalian protein

comprises an extracellular domain of a mammalian transmembrane protein. Exemplary mammalian transmembrane proteins include members of the tumor necrosis factor/nerve growth factor receptor (TNFR/NGFR) family (Farrah and Smith, *Nature* 358:26, 1992; Goodwin et al., *Cell* 73:447; 1993), which includes CD40 Ligand (CD40-L), CD27 Ligand (CD27-L), OX40 Ligand (OX40-L), and TNF. Structural studies of certain members of this family of proteins indicate that they form homotrimers. The inventive method will also be useful for other members of this family.

Additionally, many other mammalian transmembrane proteins form oligomers, either hetero-oligomers or homo-oligomers, in their biologically-active form. Members of the hematopoietin receptor family (Cosman et al., *Trends Biochem. Sci.* 15:265; 1990) are exemplary of such proteins. Gearing et al. (*Science* 255:1434, 1992) reported the cloning of a gene encoding a protein (gp130) that conferred high-affinity binding to both leukemia-inhibitory factor (LIF) and Oncostatin M (OSM) when expressed in cells along with a low-affinity LIF receptor. Similar interactions of a low-affinity receptor and a second subunit protein, resulting in a high-affinity receptor have also been proposed for other members of this family (Hayashida et al., *Proc. Natl. Acad. Sci. U.S.A.* 87:0655, 1990; Kitamura et al., *Cell* 66:1165, 1991; Tavernier et al., *Cell* 66:1175, 1991; Devos et al., *EMBO J.* 10:2133, 1991). Soluble forms of the members of the hematopoietin receptor family will exhibit higher affinity for their cognate ligand when expressed as hetero-oligomers, or in some cases, as homo-oligomers. The same will be true for other transmembrane proteins that comprise two or more subunits.

In another embodiment, the heterologous mammalian protein comprises a soluble protein such as a cytokine; the resulting fusion protein forms an oligomer. Cytokines are soluble mediators released by cells during an immune or inflammatory response, which provide antigenically non-specific, intracellular signals that are crucial in regulating physiological processes. TNF α , TNF β and certain neurotrophins such as nerve growth factor (NGF) belong to the TNF/NGF family. Modeling studies of certain members of this family indicate that they are likely to form oligomers (Goh and Porter, *Protein Eng.* 4:385, 1991; Peitsch and Jongeneel, *Int. Immunol.* 5:233, 1993). Furthermore, other cytokines, including macrophage colony stimulating factor (M-CSF; Pandit et al., *Science* 258:1358, 1992) are also known to be oligomeric. Such cytokines will also be useful in the inventive method, wherein a leucine zipper domain stabilizes the proper quaternary structure of the oligomeric cytokine.

In another embodiment, hetero-oligomeric forms of cytokines are prepared. A fusion protein of granulocyte-macrophage colony stimulating factor (GM-CSF) and Interleukin-3 (IL-3) has been shown to be a more potent proliferation stimulus than

either factor alone or IL-3 and GM-CSF combined (U.S. Patents 5,073,627 and 5,108,910). Fusion proteins comprising GM-CSF and IL-3 and DNA sequences encoding such fusion proteins are described in U.S. Patents 5,073,627 and 5,108,910, respectively, both of which are incorporated by reference herein. A similar, bivalent
5 protein composed of GM-CSF and IL3 may be formed by the expression of these cytokines as fusion proteins comprising leucine zipper domains that preferentially form heterodimers.

In another embodiment, the leucine zipper domain is removed from the fusion protein, for example by cleavage with a specific proteolytic enzyme. In addition to a
10 leucine zipper sequence and a heterologous protein, such fusion proteins also comprise an amino acid sequence recognized, and cleaved, by a selected proteolytic enzyme. The leucine zipper domain functions to stabilize the recombinant fusion protein during expression and secretion. After purification of the secreted protein, the leucine zipper is enzymatically removed by treating with the proteolytic enzyme. The heterologous
15 protein may then become monomeric. Such monomeric forms of soluble proteins will be useful as receptor antagonists, for example, by binding to a cognate receptor and preventing signaling by preventing cross-linking of the receptor.

Leucine zipper domains

20 Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al., *Science* 240:1759, 1988). Leucine zipper domain is a term used to refer to a conserved peptide domain present in these (and other) proteins, which is responsible for dimerization of the proteins. The leucine zipper domain (also referred to herein as an oligomerizing, or oligomer-forming, domain) comprises a repetitive
25 heptad repeat, with four or five leucine residues interspersed with other amino acids. Examples of leucine zipper domains are those found in the yeast transcription factor GCN4 and a heat-stable DNA-binding protein found in rat liver (C/EBP; Landschulz et al., *Science* 243:1681, 1989). Two nuclear transforming proteins, *fos* and *jun*, also exhibit leucine zipper domains, as does the gene product of the murine proto-oncogene,
30 *c-myc* (Landschulz et al., *Science* 240:1759, 1988). The products of the nuclear oncogenes *fos* and *jun* comprise leucine zipper domains preferentially form a heterodimer (O'Shea et al., *Science* 245:646, 1989; Turner and Tjian, *Science* 243:1689, 1989). The leucine zipper domain is necessary for biological activity (DNA binding) in these proteins.

35 The fusogenic proteins of several different viruses, including paramyxovirus, coronavirus, measles virus and many retroviruses, also possess leucine zipper domains (Buckland and Wild, *Nature* 338:547, 1989; Britton, *Nature* 353:394, 1991; Delwart and Mosialos, *AIDS Research and Human Retroviruses* 6:703, 1990). The leucine

zipper domains in these fusogenic viral proteins are near the transmembrane region of the proteins; it has been suggested that the leucine zipper domains could contribute to the oligomeric structure of the fusogenic proteins. Oligomerization of fusogenic viral proteins is involved in fusion pore formation (Spruce et al, *Proc. Natl. Acad. Sci. U.S.A.* 88:3523, 1991). Leucine zipper domains have also been recently reported to play a role in oligomerization of heat-shock transcription factors (Rabindran et al., *Science* 259:230, 1993).

Leucine zipper domains fold as short, parallel coiled coils. (O'Shea et al., *Science* 254:539; 1991) The general architecture of the parallel coiled coil has been well characterized, with a "knobs-into-holes" packing as proposed by Crick in 1953 (*Acta Crystallogr.* 6:689). The dimer formed by a leucine zipper domain is stabilized by the heptad repeat, designated $(abcdefg)_n$ according to the notation of McLachlan and Stewart (*J. Mol. Biol.* 98:293; 1975), in which residues *a* and *d* are generally hydrophobic residues, with *d* being a leucine, which line up on the same face of a helix. Oppositely-charged residues commonly occur at positions *g* and *e*. Thus, in a parallel coiled coil formed from two helical leucine zipper domains, the "knobs" formed by the hydrophobic side chains of the first helix are packed into the "holes" formed between the side chains of the second helix.

The leucine residues at position *d* contribute large hydrophobic stabilization energies, and are important for dimer formation (Krystek et al., *Int. J. Peptide Res.* 38:229, 1991). Lovejoy et al. recently reported the synthesis of a triple-stranded α -helical bundle in which the helices run up-up-down (*Science* 259:1288, 1993). Their studies confirmed that hydrophobic stabilization energy provides the main driving force for the formation of coiled coils from helical monomers. These studies also indicate that electrostatic interactions contribute to the stoichiometry and geometry of coiled coils.

Several studies have indicated that conservative amino acids may be substituted for individual leucine residues with minimal decrease in the ability to dimerize; multiple changes, however, usually result in loss of this ability (Landschulz et al., *Science* 243:1681, 1989; Turner and Tjian, *Science* 243:1689, 1989; Hu et al., *Science* 250:1400, 1990). van Heekeren et al. reported that a number of different amino residues can be substituted for the leucine residues in the leucine zipper domain of GCN4, and further found that some GCN4 proteins containing two leucine substitutions were weakly active (*Nucl. Acids Res.* 20:3721, 1992). Mutation of the first and second heptadic leucines of the leucine zipper domain of the measles virus fusion protein (MVF) did not affect syncytium formation (a measure of virally-induced cell fusion); however, mutation of all four leucine residues prevented fusion completely

(Buckland et al., *J. Gen. Virol.* 73:1703, 1992). None of the mutations affected the ability of MVF to form a tetramer.

Recently, amino acid substitutions in the *a* and *d* residues of a synthetic peptide representing the GCN4 leucine zipper domain have been found to change the oligomerization properties of the leucine zipper domain (Alber, Sixth Symposium of the Protein Society, San Diego, CA). When all residues at position *a* are changed to isoleucine, the leucine zipper still forms a parallel dimer. When, in addition to this change, all leucine residues at position *d* are also changed to isoleucine, the resultant peptide spontaneously forms a trimeric parallel coiled coil in solution. Substituting all amino acids at position *d* with isoleucine and at position *a* with leucine results in a peptide that tetramerizes. Peptides containing these substitutions are still referred to as leucine zipper domains since the mechanism of oligomer formation is believed to be the same as that for traditional leucine zipper domains such as those described above. However, prior to the present invention, the effect of these substitutions upon longer peptides of which the leucine zipper is but a small domain was not known, nor was it known if peptides comprising these sequences could be expressed and secreted by cells.

Preparation of Gene Fragments and Oligonucleotides

Oligonucleotide fragments of about 12 to about 20 nucleotides may be prepared according to methods that are known in the art, for example, by using an automated DNA synthesizer. Several such fragments may be synthesized, which encode overlapping portions of a peptide, for example, a leucine zipper domain. Due to the degeneracy of the genetic code, most amino acids are encoded by two or more different nucleotide triplets. The selection of a triplet to encode a given amino acid will depend upon the organism in which the final gene product is to be expressed, among other considerations. Overlapping fragments may then be joined to form a DNA encoding a peptide of interest.

A polymerase chain reaction (PCR) technique (Saiki et al., *Science* 239:487, 1988) may be employed to amplify gene fragments encoding all or a portion of a protein of interest, using 5' (upstream) and 3' (downstream) oligonucleotide primers derived from the known DNA sequence of the gene, or a gene encoding a related protein. An exemplary set of PCR conditions includes: one cycle at 94°C for 2 minutes, followed by 42°C for two minutes; 30 cycles at 72°C for 1.5 minutes, followed by 94°C for one minute, then 48°C for 1 minute; and one cycle at 72°C for seven minutes. Restriction enzyme sites can also be added to the DNA sequences of interest, in order to facilitate ligation of the resulting PCR product with a plasmid or vector, or with an additional DNA sequence or sequences. Amplified DNA sequences

may be joined substantially as described by Yon and Fried (*Nucleic Acids Res.* 17:4895; 1989).

For example, as disclosed in U.S.S.N. 08/097,827, filed July 23, 1993, the disclosure of which is incorporated by reference herein, full length mouse OX40 was cloned using 5' (upstream) and 3' (downstream) oligonucleotide primers based on the published sequence of rat OX40. The upstream primer comprised a recognition site for the restriction endonuclease *Spe* I upstream of a sequence encoding the first six (N-terminal) amino acids of rat OX40. The downstream primer comprised a recognition site for the restriction endonuclease *Spe* I upstream of a sequence encoding the last five (C-terminal) amino acids of full-length OX40. The PCR product was digested with *Spe* I, and an approximately 800 bp fragment was isolated by gel filtration, and used in a second round of PCR reaction. The isolated fragment was ligated into *Spe* I cut plasmid, pBLUESCRIPT SK® (Stratagene Cloning Systems, La Jolla, CA), which had been treated with calf intestine alkaline phosphatase (CIAP) to prevent self-ligation.

In another example, a DNA encoding only the extracellular region of a transmembrane protein can be obtained by deleting DNA encoding the intracellular and transmembrane portions of the transmembrane protein. Methods to determine which residues should be deleted and for performing the actual deletions are well known in the art. For example, Smith et al. describe a soluble form of the human CD4 antigen prepared by deleting the transmembrane and intracellular portions of the CD4 antigen (*Science* 238:1704, 1987). Treiger et al. prepared a soluble form of an Interleukin-2 receptor using similar methods using similar methods (*J. Immunol.* 136:4099, 1986).

A fusion protein may be formed from an extracellular region and a protein (or portion thereof) that is known to be secreted. For example, soluble proteins comprising an extracellular domain from a membrane-bound protein and an immunoglobulin heavy chain constant region was described by Fanslow et al., *J. Immunol.* 149:65, 1992 and by Noelle et al., *Proc. Natl. Acad. Sci. U.S.A.* 89:6550, 1992. The extracellular domain of the murine T lymphocyte antigen CD8 has also be utilized to form soluble fusion proteins (Hollenbaugh et al., *EMBO J.* 11:4313, 1992).

Preparation of Fusion Proteins

Fusion proteins are polypeptides that comprise two or more regions derived from different, or heterologous, proteins or peptides. Fusion proteins are prepared using conventional techniques of enzyme cutting and ligation of fragments from desired sequences. PCR techniques employing synthetic oligonucleotides may be used to prepare and/or amplify the desired fragments. Overlapping synthetic oligonucleotides representing the desired sequences can also be used to prepare DNA constructs encoding fusion proteins. Fusion proteins can comprise several sequences, including a

leader (or signal peptide) sequence, linker sequence, a leucine zipper sequence, or other oligomer-forming sequences, and sequences encoding highly antigenic moieties that provide a means for facile purification or rapid detection of a fusion protein.

Signal peptides facilitate secretion of proteins from cells. An exemplary signal peptide is the amino terminal 25 amino acids of the leader sequence of murine interleukin-7 (IL-7; Namen et al., *Nature* 333:571; 1988). Other signal peptides may also be employed furthermore, certain nucleotides in the IL-7 leader sequence can be altered without altering the amino acid sequence. Additionally, amino acid changes that do not affect the ability of the IL-7 sequence to act as a leader sequence can be made.

The Flag[®] octapeptide (SEQ ID NO:1; Hopp et al., *Bio/Technology* 6:1204, 1988) does not alter the biological activity of fusion proteins, is highly antigenic and provides an epitope reversibly bound by a specific monoclonal antibody, enabling rapid detection and facile purification of the expressed fusion protein. The Flag[®] sequence is also specifically cleaved by bovine mucosal enterokinase at the residue immediately following the Asp-Lys pairing. Fusion proteins capped with this peptide may also be resistant to intracellular degradation in *E. coli*. A murine monoclonal antibody that binds the Flag[®] sequence has been deposited with the ATCC under accession number HB 9259; methods of using the antibody in purification of fusion proteins comprising the Flag[®] sequence are described in U.S. Patent 5,011,912, which is incorporated by reference herein.

A protein of interest may be linked directly to another protein to form a fusion protein; alternatively, the proteins may be separated by a distance sufficient to ensure that the proteins form proper secondary and tertiary structures. Suitable linker sequences (1) will adopt a flexible extended conformation, (2) will not exhibit a propensity for developing an ordered secondary structure which could interact with the functional domains of fusion proteins, and (3) will have minimal hydrophobic or charged character which could promote interaction with the functional protein domains. Typical surface amino acids in flexible protein regions include Gly, Asn and Ser. Virtually any permutation of amino acid sequences containing Gly, Asn and Ser would be expected to satisfy the above criteria for a linker sequence. Other near neutral amino acids, such as Thr and Ala, may also be used in the linker sequence. The length of the linker sequence may vary without significantly affecting the biological activity of the fusion protein. Linker sequences are unnecessary where the proteins being fused have non-essential N- or C-terminal amino acid regions which can be used to separate the functional domains and prevent steric interference. Exemplary linker sequences are described in U.S. patents 5,073,627 and 5,108,910, the disclosures of which are incorporated by reference herein.

When an oligomeric fusion protein is formed from the extracellular portion of a transmembrane protein, a DNA sequence encoding an oligomer-forming domain, such as a leucine zipper domain, is fused to a DNA sequence encoding the extracellular region of the transmembrane protein. The members of the fusion protein are joined
5 such that the oligomer-forming domain of the fusion protein is located in the same orientation relative to the fusion protein as the transmembrane and intracytoplasmic regions of the native transmembrane protein. An oligomeric fusion protein will be stabilized by the coiled-coil interaction of leucine zipper domain. Thus, in one example, a fusion protein comprising an extracellular region derived from a ligand for
10 CD40 (CD40-L), a type II transmembrane protein described in U.S.S.N. 07/969,703, the disclosure of which is incorporated by reference herein, the oligomer-forming domain, a leucine zipper sequence, is fused to the amino-proximal end of the extracellular region. In a fusion protein derived from a type I transmembrane protein, the oligomer-forming domain would be fused to the carboxy-proximal end of the
15 extracellular region of the type I transmembrane protein. Other transmembrane proteins traverse the cell membrane more than once. Such transmembrane proteins will have two or more different extracellular regions. Soluble, oligomeric fusion proteins may also be prepared from two or more of such different extracellular regions from the same transmembrane protein.

20 Oligomeric forms of proteins that occur naturally in soluble form may also be prepared. In such cases, the oligomer-forming domain is joined to the soluble protein such that formation of an oligomer follows the conformation of the biologically active, soluble protein. Furthermore, either homo-oligomeric proteins or hetero-oligomeric proteins can be prepared, depending upon whether the oligomerizing domain(s) of
25 the fusion protein preferentially form hetero-oligomers or homo-oligomers.

Expression Vectors

Recombinant expression vectors for expression of a fusion protein comprising an oligomer-forming domain and a heterologous mammalian protein by recombinant
30 DNA techniques include a DNA sequence comprising a synthetic or cDNA-derived DNA fragment encoding an oligomer-forming domain, linked in frame to a DNA fragment encoding the heterologous protein. These DNA fragments are operably linked to suitable transcription and/or translational regulatory nucleotide sequences, such as those derived from a mammalian, microbial, viral, or insect gene. Examples of
35 regulatory sequences include sequences having a regulatory role in gene expression (e.g., a transcription promoter or enhancer), an operator sequence to control transcription, a sequence encoding an mRNA ribosomal binding site, a polyadenylation site, splice donor and acceptor sites, and appropriate sequences which

control transcription, translation initiation and termination. In addition, sequences encoding signal peptides can be incorporated into expression vectors. For example, a DNA sequence for a signal peptide (secretory leader) may be operably linked to a DNA encoding a fusion protein comprising an oligomer-forming domain and a heterologous mammalian protein. The signal peptide is expressed as a part of a precursor amino acid sequence; the signal peptide enables improved extracellular secretion of translated fusion polypeptide by a yeast host cell.

Nucleotide sequences are operably linked when the regulatory sequence functionally relates to the DNA encoding the fusion protein. Thus, a promoter nucleotide sequence is operably linked to a DNA encoding a fusion protein if the promoter nucleotide sequence controls the transcription of the DNA encoding the fusion protein. Still further, a ribosome binding site may be operably linked to a sequence for a fusion protein if the ribosome binding site is positioned within the vector to encourage translation.

Transcription and translational control sequences for mammalian host cell expression vectors may be excised from viral genomes. For example, commonly used mammalian cell promoter sequences and enhancer sequences are derived from Polyoma virus, Adenovirus 2, Simian Virus 40 (SV40), and human cytomegalovirus. DNA sequences derived from the SV40 viral genome, for example, the SV40 origin, early and late promoters, enhancer, splice, and polyadenylation sites may be used to provide the other genetic elements required for expression of a structural gene sequence in a mammalian host cell. Viral early and late promoters are particularly useful because both are easily obtained from a viral genome as a fragment which may also contain a viral origin of replication (Fiers et al., *Nature* 273:113, 1978). Smaller or larger SV40 fragments may also be used, provided the approximately 250 bp sequence extending from the *Hind* III site toward the *Bgl* I site located in the SV40 viral origin of replication site is included.

Exemplary mammalian expression vectors can be constructed as disclosed by Okayama and Berg (*Mol. Cell. Biol.* 3:280, 1983). A useful high expression vector, PMLSV N1/N4, described by Cosman et al., *Nature* 312:768, 1984 has been deposited as ATCC 39890. Additional useful mammalian expression vectors are described in EP-A-0367566, and in U.S. Patent Application Serial No. 07/701,415, filed May 16, 1991, incorporated by reference herein. For expression of a type II protein extracellular region, such as OX40-L, a heterologous signal sequence may be added, such as the signal sequence for interleukin-7 (IL-7) described in United States Patent 4,965,195, or the signal sequence for interleukin-2 receptor described in United States Patent Application 06/626,667 filed on July 2, 1984. Another exemplary vector is

pDC406, which includes regulatory sequences derived from SV40, human immunodeficiency virus (HIV), and Epstein-Barr virus (EBV).

Expression vectors transfected into prokaryotic host cells generally comprise one or more phenotypic selectable markers. A phenotypic selectable marker is, for example, a gene encoding a protein that confers antibiotic resistance or that supplies an autotrophic requirement, and an origin of replication recognized by the host to ensure amplification within the host. Other useful expression vectors for prokaryotic host cells include a selectable marker of bacterial origin derived from commercially available plasmids. This selectable marker can comprise genetic elements of the cloning vector pBR322 (ATCC 37017). pBR322 contains genes for ampicillin and tetracycline resistance and thus provides simple means for identifying transformed cells. The pBR322 "backbone" sections are combined with an appropriate promoter and a OX40-L DNA sequence. Other commercially vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and pGEM1 (Promega Biotec, Madison, WI, USA).

Promoter sequences are commonly used for recombinant prokaryotic host cell expression vectors. Common promoter sequences include β -lactamase (penicillinase), lactose promoter system (Chang et al., *Nature* 275:615, 1978; and Goeddel et al., *Nature* 281:544, 1979), tryptophan (trp) promoter system (Goeddel et al., *Nucl. Acids Res.* 8:4057, 1980; and EP-A-36776) and tac promoter (Maniatis, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, p. 412, 1982). A particularly useful prokaryotic host cell expression system employs a phage λ P_L promoter and a cI857ts thermolabile repressor sequence. Plasmid vectors available from the American Type Culture Collection which incorporate derivatives of the λ P_L promoter include plasmid pHUB2 (resident in *E. coli* strain JMB9 (ATCC 37092)) and pPLc28 (resident in *E. coli* RR1 (ATCC 53082)).

Host Cells

Suitable host cells for expression of a fusion protein comprising an oligomer-forming domain and a heterologous mammalian protein include prokaryotes and yeast or higher eukaryotic cells. Prokaryotes include gram negative or gram positive organisms, for example, *E. coli* or *Bacilli*. Suitable prokaryotic host cells for transformation include, for example, *E. coli*, *Bacillus subtilis*, *Salmonella typhimurium*, and various other species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*. Higher eukaryotic cells include established cell lines of mammalian origin. Cell-free translation systems could also be employed to produce a fusion protein comprising an oligomer-forming domain and a heterologous mammalian protein using an RNA derived from DNA constructs disclosed herein.

In a prokaryotic host cell, such as *E. coli*, a fusion protein may include an N-terminal methionine residue to facilitate expression of the recombinant polypeptide in the prokaryotic host cell. The N-terminal Met may be cleaved from the expressed recombinant fusion protein. Prokaryotic host cells may be used for expression of fusion proteins that do not require extensive proteolytic or disulfide processing.

Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts are described, for example, in Pouwels et al. *Cloning Vectors: A Laboratory Manual*, Elsevier, New York, (1985). An expression vector carrying the recombinant fusion protein DNA is transfected or transformed into a substantially homogeneous culture of a suitable host microorganism or mammalian cell line according to methods that are known in the art, to form transfected or transformed host cells that express the fusion protein. Expressed fusion protein will be located within the host cell and/or secreted into culture supernatant fluid, depending upon the nature of the host cell and the gene construct inserted into the host cell.

A fusion protein comprising an oligomer-forming domain and a heterologous mammalian protein may be expressed in yeast host cells, preferably from the *Saccharomyces* genus (e.g., *S. cerevisiae*). Other genera of yeast, such as *Pichia* or *Kluyveromyces*, may also be employed. Yeast vectors will often contain an origin of replication sequence from a 2 μ yeast plasmid, an autonomously replicating sequence (ARS), a promoter region, sequences for polyadenylation, and sequences for transcription termination. Preferably, yeast vectors include an origin of replication sequence and selectable marker. Suitable promoter sequences for yeast vectors include promoters for metallothionein, 3-phosphoglycerate kinase (Hitzeman et al., *J. Biol. Chem.* 255:2073, 1980) or other glycolytic enzymes (Hess et al., *J. Adv. Enzyme Reg.* 7:149, 1968; and Holland et al., *Biochem.* 17:4900, 1978), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. Other suitable vectors and promoters for use in yeast expression are further described in Hitzeman, EPA-73,657.

Yeast vectors can be assembled, for example, using DNA sequences from pBR322 for selection and replication in *E. coli* (Amp^r gene and origin of replication). Other yeast DNA sequences that can be included in a yeast expression construct include a glucose-repressible ADH2 promoter and α -factor secretion leader. The ADH2 promoter has been described by Russell et al. (*J. Biol. Chem.* 258:2674, 1982) and Beier et al. (*Nature* 300:724, 1982). The yeast α -factor leader sequence directs secretion of heterologous polypeptides. The α -factor leader sequence is often inserted between the promoter sequence and the structural gene sequence. See, e.g., Kurjan et

al., *Cell* 30:933, 1982 and Bitter et al., *Proc. Natl. Acad. Sci. USA* 81:5330, 1984. Other leader sequences suitable for facilitating secretion of recombinant polypeptides from yeast hosts are known to those of skill in the art. A leader sequence may be modified near its 3' end to contain one or more restriction sites. This will facilitate fusion of the leader sequence to the structural gene.

Yeast transformation protocols are known to those of skill in the art. One such protocol is described by Hinnen et al., *Proc. Natl. Acad. Sci. USA* 75:1929, 1978. For example, one can select for Trp⁺ transformants in a selective medium, wherein the selective medium consists of 0.67% yeast nitrogen base, 0.5% casamino acids, 2% glucose, 10 µg/ml adenine and 20 µg/ml uracil. Yeast host cells transformed by vectors containing ADH2 promoter sequence may be grown for inducing expression in a "rich" medium. An example of a rich medium is one consisting of 1% yeast extract, 2% peptone, and 1% glucose supplemented with 80 µg/ml adenine and 80 µg/ml uracil. Derepression of the ADH2 promoter occurs when glucose is exhausted from the medium.

Mammalian or insect host cell culture systems could also be employed to express recombinant fusion protein. Examples of suitable mammalian host cell lines include the COS-7 line of monkey kidney cells (ATCC CRL 1651; Gluzman et al., *Cell* 23:175, 1981), L cells, C127 cells, 3T3 cells (ATCC CRL 163), Chinese hamster ovary (CHO) cells, HeLa cells, BHK (ATCC CRL 10) cell lines, and CV-1/EBNA cells (ATCC CRL 10478). The CV-1/EBNA cell line was derived by transfection of the CV-1 cell line with a gene encoding Epstein-Barr virus nuclear antigen-1 (EBNA-1) and constitutively express EBNA-1 driven from human CMV immediate-early enhancer/promoter. An EBNA-1 gene allows for episomal replication of expression vectors that contain the EBV origin of replication.

Protein Purification

Purified soluble fusion proteins are prepared by culturing suitable host/vector systems to express the recombinant soluble fusion proteins, which are then purified from culture media or cell extracts, using standard methods of protein purification that are optimized for each individual soluble fusion protein.

For example, supernatants from systems which secrete recombinant protein into culture media are clarified, and concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. Following the concentration step, the concentrate can be applied to a suitable purification matrix. Suitable matrices include those useful in affinity chromatography. For example, a suitable affinity matrix can comprise a cognate protein to which the

fusion proteins binds, or lectin or antibody molecule which binds the fusion protein, bound to a suitable support.

Alternatively, an ion exchange resin can be employed, for example, an anion exchange resin comprising a matrix or substrate having pendant diethylaminoethyl (DEAE) groups, or other suitable anion exchangers. The matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification. Alternatively, a cation exchange step can be employed. Suitable cation exchangers include various insoluble matrices comprising sulfopropyl or carboxymethyl groups.

One or more reversed-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify a soluble fusion protein. Size exclusion chromatography will also be useful in purifying soluble fusion proteins. Additionally, hydrophobic supports can also be used under low pressure conditions; an exemplary medium is phenyl-sepharose. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a homogeneous recombinant protein.

Biological Activity

Biological activity of recombinant, soluble fusion proteins is mediated by binding of the recombinant, soluble fusion protein to a cognate molecule. A cognate molecule is defined as a molecule which binds the recombinant soluble fusion protein in a non-covalent interaction based upon the proper conformation of the recombinant soluble fusion protein and the cognate molecule. For example, for a recombinant soluble fusion protein comprising an extracellular region of a receptor, the cognate molecule comprises a ligand which binds the extracellular region of the receptor. Conversely, for a recombinant soluble fusion protein comprising a ligand, the cognate molecule comprises a receptor (or binding protein) which binds the ligand.

Binding of a recombinant fusion protein to a cognate molecule is a marker for biological activity. Such binding activity may be determined, for example, by competition for binding to the binding domain of the cognate molecule (i.e. competitive binding assays). One configuration of a competitive binding assay for a recombinant soluble fusion protein comprising a ligand uses a radiolabeled, soluble receptor, and intact cells expressing a native form of the ligand. Such an assay is illustrated in Example 4 herein. Similarly, a competitive assay for a recombinant soluble fusion protein comprising a receptor uses a radiolabeled, soluble ligand, and intact cells expressing a native form of the receptor. Instead of intact cells expressing a native form of the cognate molecule, one could substitute purified cognate molecule bound to a solid phase. Competitive binding assays can be performed using standard

methodology: Qualitative or semi-quantitative results can be obtained by competitive autoradiographic plate binding assays, or fluorescence activated cell sorting, or Scatchard plots may be utilized to generate quantitative results.

Biological activity may also be measured using bioassays that are known in the art, such as a cell proliferation assay. Exemplary bioassays are described in Example 2 herein. The type of cell proliferation assay used will depend upon the recombinant soluble fusion protein. A bioassay for a recombinant soluble fusion protein that in its native form acts upon T cells will utilize purified T cells obtained by methods that are known in the art. Such bioassays include costimulation assays in which the purified T cells are incubated in the presence of the recombinant soluble fusion protein and a suboptimal level of a mitogen such as Con A or PHA. Similarly, purified B cells will be used for a recombinant soluble fusion protein that in its native form acts upon B cells. Other types of cells may also be selected based upon the cell type upon which the native form of the recombinant soluble fusion protein acts. Proliferation is determined by measuring the incorporation of a radiolabeled substance, such as ^3H thymidine, according to standard methods.

Yet another type assay for determining biological activity is induction of secretion of secondary molecules. For example, certain proteins induce secretion of cytokines by T cells. T cells are purified and stimulated with a recombinant soluble fusion protein under the conditions required to induce cytokine secretion (for example, in the presence of a comitogen). Induction of cytokine secretion is determined by bioassay, measuring the proliferation of a cytokine dependent cell line. Similarly, induction of immunoglobulin secretion is determined by measuring the amount of immunoglobulin secreted by purified B cells stimulated with a recombinant soluble fusion protein that acts on B cells in its native form, using a quantitative (or semi-quantitative) assay such as an enzyme immunoassay. Example 2 presents such assays.

The relevant disclosures of all references cited herein are specifically incorporated by reference. The following examples are offered by way of illustration, and not by way of limitation.

EXAMPLE 1

This example describes construction of a CD40-L DNA construct to express a soluble CD40-L fusion protein referred to as trimeric CD40-L. CD40-L is a type II transmembrane protein found on activated T cells, that acts as a ligand for the B cell antigen, CD40 (Armitage et al., *Nature* 357:80, 1992; Spriggs et al., *J. Exp. Med.* 176:1543, 1992). A gene encoding CD40-L has been cloned and sequenced as described in U.S.S.N. 07/969,703, filed October 23, 1992, the disclosure of which is incorporated by reference herein. CD40-L is a member of the Tumor Necrosis Factor

(TNF) family of proteins; several members of this family are believed to exist in trimeric form.

Trimeric CD40-L contains a leader sequence, a 33 amino acid sequence referred to as a "leucine zipper" (SEQ ID NO:2), and an eight amino acid hydrophilic sequence described by Hopp et al. (Hopp et al., *Bio/Technology* 6:1204, 1988; SEQ ID NO:1; referred to as Flag[®]), followed by the extracellular region of human CD40-L (amino acid 50 to amino acid 261 of SEQ ID NOs:3 and 4). The utility of the leader and the Flag[®] sequences have been described in previously. The 33 amino acid sequence presented in SEQ ID NO:2 trimerizes spontaneously in solution. Fusion proteins comprising this 33 amino acid sequence are thus expected to form trimers or multimers spontaneously.

The construct is prepared by synthesizing oligonucleotides representing a leader sequence, the 33 amino acid sequence described above (SEQ ID NO:2), and the Flag[®] sequence (SEQ ID NO:1), then ligating the final product to a DNA fragment encoding the extracellular region of human CD40-L (amino acids 50 to 261 of SEQ ID NOs:3 and 4).

The resulting ligation product in expression vector pDC406 was transfected into the monkey kidney cell line CV-1/EBNA (ATCC CRL 10478). The pDC406 plasmid includes regulatory sequences derived from SV40, human immunodeficiency virus (HIV), and Epstein-Barr virus (EBV). The CV-1/EBNA cell line was derived by transfection of the CV-1 cell line with a gene encoding Epstein-Barr virus nuclear antigen-1 (EBNA-1) that constitutively expresses EBNA-1 driven from the human CMV intermediate-early enhancer/promoter. The EBNA-1 gene allows for episomal replication of expression vectors, such as pDC406, that contain the EBV origin of replication.

Once cells expressing the fusion construct are identified, large scale cultures of transfected cells are grown to accumulate supernatant from cells expressing soluble, oligomeric CD40-L. The soluble, oligomeric CD40-L fusion protein in supernatant fluid is purified by affinity purification substantially as described in U.S. Patent 5,011,912. sCD40-L may also be purified using other protein purification methods, as described herein. Silver-stained SDS gels of the soluble, oligomeric CD40-L fusion protein can be prepared to determine purity. Similar methods are used to prepare and purify a trimer-forming construct comprising the extracellular region of murine CD40-L (amino acid 50 to amino acid 260 of SEQ ID NOs:5 and 6). Soluble CD40-L exhibits similar biological activity to that of membrane-bound CD40-L, as shown in Example 2.

Example 2

This example illustrates B cell proliferative activity and induction of polyclonal immunoglobulin secretion using soluble, oligomeric CD40-L prepared as described in Example 1. Human B cells were purified substantially as described in Armitage et al. (J. Immunol. 150:3671; 1993). Briefly, tonsillar tissue was gently teased and the resulting cell suspension centrifuged over Histopaque® (Sigma, St. Louis, MO). T cell-depleted preparations of cells (E⁻) were obtained by removing T cells by rosetting with 2-aminoethylisothiuronium bromide-treated SRBC (sheep red blood cells) and treatment with B cell Lympho-kwik (One Lambda Inc., Los Angeles, CA) for 1 hour at 37°C to lyse contaminating non-B cells. Peripheral blood mononuclear cells (PBMC) were isolated in the same manner, with the additional step of treating the partially purified cells with 5 mM leucine methyl ester (Leu ME; Sigma, St. Louis, MO) in serum-free medium for one hour at room temperature prior to the Lympho-kwik step, to remove phagocytic cells.

B cell proliferation was measured with a ³H-thymidine incorporation assay, substantially as described in Armitage et al., *supra*. Cells were cultured for three days in the presence of soluble, oligomeric CD40-L, alone or in the presence of 5 ng/ml IL-4 (Immunex Corporation, Seattle, WA), 5 µg/ml anti-IgM coated beads (BioRad, Richmond, CA), or a combination of IL-4 and anti-IgM. The results of a representative experiment to evaluate the ability of soluble, oligomeric CD40-L to induce B cell proliferation are shown in Figures 1A and 1B. sCD40-L induced proliferation of tonsillar B cells in the presence of IL-4, anti-IgM, or a combination of these to co-factors (Figure 1A). sCD40-L also induced proliferation of peripheral blood B cells in the presence of IL-4, anti-IgM, or a combination of these to co-factors, and with B cells obtained from some donors, a moderate level of proliferation in the absence of any co-factor (Figure 1B). These results parallel the results obtained with recombinant, membrane-bound CD40-L described in Armitage et al. *supra*.

Polyclonal immunoglobulin secretion was determined by isotype-specific ELISA on supernatant fluid from 10 day cultures of 1 X 10⁵ B cells per well, substantially as described in Armitage et al., *supra*. Purified B cells were stimulated with a 1:20 dilution of supernatant fluid containing soluble, oligomeric CD40-L (sCD40-L), a 1:20 dilution of control supernatant (control S/N; conditioned medium from cells transfected with vector alone), or transfected CV-1/EBNA cells expressing membrane-bound CD40-L (CV1/CD40L; 3 x 10⁴ cells/well), in the presence or absence of 10 ng/ml of either IL-2, IL-4 (both from Immunex Corporation, Seattle, WA) or IL-10 (Genzyme Corporation, Boston, MA). The results of a representative experiment measuring immunoglobulin secretion are presented in Table 1; values given represent

the quantity of each isotype secreted by the induced B cells in ng/ml, as measured by ELISA.

Table 1: Immunoglobulin Secretion Induced by CD40 Ligand

	Medium alone	Medium + IL-2	Medium + IL-4	Medium + IL-10	Isotype
Control S/N	114.9	424.5	69.4	132.2	IgM
sCD40L-3	212.3	2827.5	51.5	1726.5	
CV1/CD40L	91.8	1965.0	97.4	574.1	
Control S/N	16.2	161.0	40.1	22.7	IgG ₁
sCD40L-3	25.8	933.2	122.3	231.9	
CV1/CD40L	2.3	428.0	27.9	247.0	
Control S/N	45.1	44.2	39.6	50.0	IgA
sCD40L-3	56.7	248.0	48.7	353.9	
CV1/CD40L	64.7	513.8	34.7	447.2	
Control S/N	<0.3	<0.3	<0.3	<0.3	IgE
sCD40L-3	<0.3	<0.3	67.0	<0.3	
CV1/CD40L	<0.3	<0.3	77.6	<0.3	

5

These results indicated that soluble, oligomeric CD40-L induced polyclonal immunoglobulin secretion in the same manner as membrane-bound CD40-L. IL-2 and IL-10 enhanced secretion of IgM, IgG₁ and IgA; secretion of measurable amounts of IgE occurred only in the presence of IL-4, just as observed for membrane-bound CD40-L. The same pattern of immunoglobulin secretion was present when B cells from several different donors were tested, although the absolute quantities varied from donor to donor. In similar experiments in a murine system, a soluble, oligomeric construct of a murine CD40-L also gave comparable results to membrane-bound murine CD40-L.

15

Example 3

This example describes construction of a CD27-L DNA construct to express a soluble, oligomeric CD27-L fusion protein referred to as sCD27L-3. CD27-L is a type II transmembrane protein that binds to the lymphocyte antigen, CD27. CD27 is found on most peripheral blood T cells (Bigler et al., *J. Immunol.* 141:21, 1988; van Lier et al., *Eur. J. Immunol.* 18:811, 1988), and a subpopulation of B cells (Maurer et al., *Eur. J. Immunol.* 20:2679, 1990). CD27-L is a member of the tumor necrosis factor family of cytokines. A gene encoding CD27-L has been cloned and sequenced as

20

described in Goodwin et al., *Cell* 73:447 (1993), and in U.S.S.N. _____, filed _____, a continuation-in-part of U.S.S.N. 07/941,648, filed September 8, 1992, the disclosures of which are incorporated by reference herein.

5 The construct encoding sCD27L-3 contains a leader sequence, a 37 amino acid sequence comprising a leucine zipper domain, and the extracellular region of human CD27-L from amino acid 39 to amino acid 193; the nucleotide and amino acids sequences are presented in SEQ ID NOs:7 and 7. The construct was prepared by using methods that are well-known in the art to obtain a DNA encoding the extracellular region of CD27-L. Briefly, the extracellular region of CD27-L was amplified from a
10 full-length CD27-L cDNA using a PCR technique. The primers used were derived from the extracellular region of CD27-L (SEQ ID NO:7, nucleotides 222-245, for the 5' primer, and the complement of nucleotides 663-689 for the 3' primer) with addition of sequences encoding desired restriction enzyme sites (ACTAGT, which contains a *Spe* I site, for the 5' primer, and GCGGCCGC, which contains a *Not* I site, for the 3'
15 primer). The amplified PCR product, representing the extracellular domain of CD27-L, was cloned into an *Spe* I/*Not* I-cut SMAG (pDC206) vector. SMAG vector is a derivative of pDC201 (Sims et al., *Science* 241:585, 1988) that contains the murine IL-7 leader sequence. The vector was amplified, then cut with *Spe* I and treated with calf intestinal alkaline phosphatase. Oligonucleotides based on the amino acid sequence of a leucine zipper (SEQ ID NO:1) were synthesized by standard methodology, and ligated
20 with the *Spe* I-cut vector, to form an expression vector comprising a murine IL-7 leader sequence (Namen et al., *Nature* 333:571; 1988), a leucine zipper domain, and the extracellular domain of CD27-L. The expression vector was referred to as pDC206/sCD27L-3.

25 pDC206/sCD27L-3 was co-transfected into the monkey kidney cell line CV-1/EBNA (ATCC CRL 10478) along with a pSV3Neo plasmid. pSV3Neo (Mulligan and Berg, *Proc. Natl. Acad. Sci. U.S.A.* 78:2072; 1981) is a plasmid which expresses the SV40 T antigen, and thus allows for the episomal replication of the pDC206 plasmid.

30 Once cells expressing the fusion construct are identified, large scale cultures of transfected cells are grown to accumulate supernatant from cells expressing the soluble, oligomeric CD27-L fusion protein (referred to as sCD27L-3). sCD27L-3 in supernatant fluid is purified by affinity purification substantially as described in U.S. Patent 5,011,912. sCD27L-3 may also be purified using other protein purification
35 methods, as described herein. Silver-stained SDS gels of the soluble, oligomeric CD27-L fusion protein can be prepared to determine purity. sCD27L-3 binds to soluble CD27, and inhibits binding of soluble CD27 to cells expressing CD27-L, as described in Example 4.

Example 4

This example illustrates a binding inhibition activity of sCD27L-3. A soluble form of the human lymphocyte surface antigen CD27 was prepared substantially as described by Fanslow et al., *J. Immunol.* 149:65 (1992), to form a dimeric, Fc fusion construct referred to as CD27.Fc (Goodwin et al., *Cell* 73:447; 1993). CD27.Fc comprises the extracellular region of CD27 and an Fc region from a human IgG₁. sCD27L-3 inhibits binding of CD27.Fc to MP.1 cell, a human, Epstein-Barr virus-transformed B cell line that expresses endogenous CD27-L.

Conditioned supernatant fluid from CV-1/EBNA cells transfected with pDC206/sCD27L-3 was titrated in a 96 well plate. A constant amount of CD27.Fc (1 µg/well) was added to each well, followed by $1-2 \times 10^6$ MP.1 cells per well, in binding medium (RPMI-1640 containing 1 % bovine serum albumin, 0.2 % sodium azide and 20 mM HEPES, pH 7.2). The plate was incubated at 37°C for one hour. Cells were washed twice with PBS, then pelleted by centrifugation. ¹²⁵I-mouse anti-human IgG Fc was added to each well at a constant concentration, and the plate incubated for an additional hour at 37°C. The ¹²⁵I-mouse anti-human IgG Fc bound to the CD27.Fc that bound to the MP.1 cells. After the final incubation, cells were harvested over phthalate oil-containing tubes to separate the bound and free ¹²⁵I-mouse anti-human IgG Fc, and the amount of radioactivity quantitated using a gamma counter.

The results of this experiment are presented in Figure 2. sCD27L-3 exhibited a dose-dependent inhibition of the binding of CD27.Fc to MP.1 cells. By comparing the concentration at which the inhibition of binding of CD27.Fc is at 50% to the titration of inhibition by sCD27L-3, it was estimated that the concentration of sCD27L-3 in the conditioned medium was between 18 and 40 µg/ml. In making this comparison, the MW of sCD27L-3 was estimated to be 135 Kd (estimated MW of extracellular region of CD27-L was 45 Kd, multiplied by three for formation of trimer), and the binding of sCD27L-3 to CD27.Fc was assumed to occur at a molar ratio. The K_i was estimated to be 10 times the K_d , which was $3 \times 10^{-7} \text{M}^{-1}$, and the initial concentration was assumed to be $1 \times 10^{-8} \text{M}$. The results demonstrated that the initial assumption of a concentration of $1 \times 10^{-8} \text{M}$ was approximately 10-fold too low, and a 1:3 dilution of the supernatant fluid actually gave an estimated concentration of $1 \times 10^{-7} \text{M}$.

SEQUENCE LISTING

- (1) GENERAL INFORMATION:
- 5 (i) APPLICANT: Spriggs, Melanie
Srinivasan, Subhashini
- 10 (ii) TITLE OF INVENTION: Methods of Preparing Soluble,
Oligomeric Proteins
- (iii) NUMBER OF SEQUENCES: 8
- 15 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Immunex Corporation
(B) STREET: 51 University Street
(C) CITY: Seattle
(D) STATE: WA
20 (E) COUNTRY: USA
(F) ZIP: 98101
- (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
25 (B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
30 (A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
35 (A) NAME: Perkins, Patricia A
(B) REGISTRATION NUMBER: 34,693
(C) REFERENCE/DOCKET NUMBER: 1003
- (ix) TELECOMMUNICATION INFORMATION:
40 (A) TELEPHONE: (206) 587-0430
(B) TELEFAX: (206) 233-0644
- (2) INFORMATION FOR SEQ ID NO:1:
- 45 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
50 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- 55 (iv) ANTI-SENSE: NO
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
- 60 Asp Tyr Lys Asp Asp Asp Asp Lys
1 5

(2) INFORMATION FOR SEQ ID NO:2:

5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 33 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

15 Arg Met Lys Gln Ile Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys Ile
 1 5 10 15
 Tyr His Ile Glu Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly Glu
 20 20 25 30
 Arg

(2) INFORMATION FOR SEQ ID NO:3:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 786 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 30 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

35 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

40 (A) ORGANISM: Human
 (B) STRAIN: CD40-L

(ix) FEATURE:

45 (A) NAME/KEY: CDS
 (B) LOCATION: 1..783

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

50 ATG ATC GAA ACA TAC AAC CAA ACT TCT CCC CGA TCT GCG GCC ACT GGA 48
 Met Ile Glu Thr Tyr Asn Gln Thr Ser Pro Arg Ser Ala Ala Thr Gly
 1 5 10 15
 CTG CCC ATC AGC ATG AAA ATT TTT ATG TAT TTA CTT ACT GTT TTT CTT 96
 Leu Pro Ile Ser Met Lys Ile Phe Met Tyr Leu Leu Thr Val Phe Leu
 55 20 25 30
 ATC ACC CAG ATG ATT GGG TCA GCA CTT TTT GCT GTG TAT CTT CAT AGA 144
 Ile Thr Gln Met Ile Gly Ser Ala Leu Phe Ala Val Tyr Leu His Arg
 60 35 40 45

	AGG	TTG	GAC	AAG	ATA	GAT	GAA	AGG	AAT	CTT	CAT	GAA	GAT	TTT	GTA	192	
	Arg	Leu	Asp	Lys	Ile	Glu	Asp	Glu	Arg	Asn	Leu	His	Glu	Asp	Phe	Val	
		50					55					60					
5	TTC	ATG	AAA	ACG	ATA	CAG	AGA	TGC	AAC	ACA	GGA	GAA	AGA	TCC	TTA	TCC	240
	Phe	Met	Lys	Thr	Ile	Gln	Arg	Cys	Asn	Thr	Gly	Glu	Arg	Ser	Leu	Ser	
	65					70					75					80	
10	TTA	CTG	AAC	TGT	GAG	GAG	ATT	AAA	AGC	CAG	TTT	GAA	GGC	TTT	GTG	AAG	288
	Leu	Leu	Asn	Cys	Glu	Glu	Ile	Lys	Ser	Gln	Phe	Glu	Gly	Phe	Val	Lys	
					85					90					95		
15	GAT	ATA	ATG	TTA	AAC	AAA	GAG	GAG	ACG	AAG	AAA	GAA	AAC	AGC	TTT	GAA	336
	Asp	Ile	Met	Leu	Asn	Lys	Glu	Glu	Thr	Lys	Lys	Glu	Asn	Ser	Phe	Glu	
				100					105					110			
20	ATG	CAA	AAA	GGT	GAT	CAG	AAT	CCT	CAA	ATT	GCG	GCA	CAT	GTC	ATA	AGT	384
	Met	Gln	Lys	Gly	Asp	Gln	Asn	Pro	Gln	Ile	Ala	Ala	His	Val	Ile	Ser	
			115					120					125				
25	GAG	GCC	AGC	AGT	AAA	ACA	ACA	TCT	GTG	TTA	CAG	TGG	GCT	GAA	AAA	GGA	432
	Glu	Ala	Ser	Ser	Lys	Thr	Thr	Ser	Val	Leu	Gln	Trp	Ala	Glu	Lys	Gly	
		130					135					140					
30	TAC	TAC	ACC	ATG	AGC	AAC	AAC	TTG	GTA	ACC	CTG	GAA	AAT	GGG	AAA	CAG	480
	Tyr	Tyr	Thr	Met	Ser	Asn	Asn	Leu	Val	Thr	Leu	Glu	Asn	Gly	Lys	Gln	
	145					150					155					160	
35	CTG	ACC	GTT	AAA	AGA	CAA	GGA	CTC	TAT	TAT	ATC	TAT	GCC	CAA	GTC	ACC	528
	Leu	Thr	Val	Lys	Arg	Gln	Gly	Leu	Tyr	Tyr	Ile	Tyr	Ala	Gln	Val	Thr	
					165				170						175		
40	TTC	TGT	TCC	AAT	CGG	GAA	GCT	TCG	AGT	CAA	GCT	CCA	TTT	ATA	GCC	AGC	576
	Phe	Cys	Ser	Asn	Arg	Glu	Ala	Ser	Ser	Gln	Ala	Pro	Phe	Ile	Ala	Ser	
				180				185						190			
45	CTC	TGC	CTA	AAG	TCC	CCC	GGT	AGA	TTC	GAG	AGA	ATC	TTA	CTC	AGA	GCT	624
	Leu	Cys	Leu	Lys	Ser	Pro	Gly	Arg	Phe	Glu	Arg	Ile	Leu	Leu	Arg	Ala	
			195					200					205				
50	GCA	AAT	ACC	CAC	AGT	TCC	GCC	AAA	CCT	TGC	GGG	CAA	CAA	TCC	ATT	CAC	672
	Ala	Asn	Thr	His	Ser	Ser	Ala	Lys	Pro	Cys	Gly	Gln	Gln	Ser	Ile	His	
		210					215					220					
55	TTG	GGA	GGA	GTA	TTT	GAA	TTG	CAA	CCA	GGT	GCT	TCG	GTG	TTT	GTC	AAT	720
	Leu	Gly	Gly	Val	Phe	Glu	Leu	Gln	Pro	Gly	Ala	Ser	Val	Phe	Val	Asn	
	225					230					235					240	
60	GTG	ACT	GAT	CCA	AGC	CAA	GTG	AGC	CAT	GGC	ACT	GGC	TTC	ACG	TCC	TTT	768
	Val	Thr	Asp	Pro	Ser	Gln	Val	Ser	His	Gly	Thr	Gly	Phe	Thr	Ser	Phe	
					245					250</							

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 261 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Ile Glu Thr Tyr Asn Gln Thr Ser Pro Arg Ser Ala Ala Thr Gly
1 5 10 15
15 Leu Pro Ile Ser Met Lys Ile Phe Met Tyr Leu Leu Thr Val Phe Leu
20 25 30
Ile Thr Gln Met Ile Gly Ser Ala Leu Phe Ala Val Tyr Leu His Arg
35 40 45
20 Arg Leu Asp Lys Ile Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val
50 55 60
25 Phe Met Lys Thr Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser
65 70 75 80
Leu Leu Asn Cys Glu Glu Ile Lys Ser Gln Phe Glu Gly Phe Val Lys
85 90 95
30 Asp Ile Met Leu Asn Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu
100 105 110
Met Gln Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser
115 120 125
35 Glu Ala Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly
130 135 140
40 Tyr Tyr Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln
145 150 155 160
Leu Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr
165 170 175
45 Phe Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser
180 185 190
Leu Cys Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala
195 200 205
50 Ala Asn Thr His Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His
210 215 220
55 Leu Gly Gly Val Phe Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn
225 230 235 240
Val Thr Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe
245 250 255
60 Gly Leu Leu Lys Leu
260

(2) INFORMATION FOR SEQ ID NO:5:

5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 783 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

15 (iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: Mouse
 (B) STRAIN: CD40-L

20 (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 1..780

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATG	ATA	GAA	ACA	TAC	AGC	CAA	CCT	TCC	CCC	AGA	TCC	GTG	GCA	ACT	GGA	48
Met	Ile	Glu	Thr	Tyr	Ser	Gln	Pro	Ser	Pro	Arg	Ser	Val	Ala	Thr	Gly	
1				5					10					15		
CTT	CCA	GCG	AGC	ATG	AAG	ATT	TTT	ATG	TAT	TTA	CTT	ACT	GTT	TTC	CTT	96
Leu	Pro	Ala	Ser	Met	Lys	Ile	Phe	Met	Tyr	Leu	Leu	Thr	Val	Phe	Leu	
			20					25					30			
ATC	ACC	CAA	ATG	ATT	GGA	TCT	GTG	CTT	TTT	GCT	GTG	TAT	CTT	CAT	AGA	144
Ile	Thr	Gln	Met	Ile	Gly	Ser	Val	Leu	Phe	Ala	Val	Tyr	Leu	His	Arg	
		35					40					45				
AGA	TTG	GAT	AAG	GTC	GAA	GAG	GAA	GTA	AAC	CTT	CAT	GAA	GAT	TTT	GTA	192
Arg	Leu	Asp	Lys	Val	Glu	Glu	Glu	Val	Asn	Leu	His	Glu	Asp	Phe	Val	
	50					55					60					
TTC	ATA	AAA	AAG	CTA	AAG	AGA	TGC	AAC	AAA	GGA	GAA	GGA	TCT	TTA	TCC	240
Phe	Ile	Lys	Lys	Leu	Lys	Arg	Cys	Asn	Lys	Gly	Glu	Gly	Ser	Leu	Ser	
45	65				70				75					80		
TTG	CTG	AAC	TGT	GAG	GAG	ATG	AGA	AGG	CAA	TTT	GAA	GAC	CTT	GTC	AAG	288
Leu	Leu	Asn	Cys	Glu	Glu	Met	Arg	Arg	Gln	Phe	Glu	Asp	Leu	Val	Lys	
			85					90					95			
GAT	ATA	ACG	TTA	AAC	AAA	GAA	GAG	AAA	AAA	GAA	AAC	AGC	TTT	GAA	ATG	336
Asp	Ile	Thr	Leu	Asn	Lys	Glu	Glu	Lys	Lys	Glu	Asn	Ser	Phe	Glu	Met	
			100					105					110			
CAA	AGA	GGT	GAT	GAG	GAT	CCT	CAA	ATT	GCA	GCA	CAC	GTT	GTA	AGC	GAA	384
Gln	Arg	Gly	Asp	Glu	Asp	Pro	Gln	Ile	Ala	Ala	His	Val	Val	Ser	Glu	
		115					120					125				
GCC	AAC	AGT	AAT	GCA	GCA	TCC	GTT	CTA	CAG	TGG	GCC	AAG	AAA	GGA	TAT	432
Ala	Asn	Ser	Asn	Ala	Ala	Ser	Val	Leu	Gln	Trp	Ala	Lys	Lys	Gly	Tyr	
	130					135					140					

5	TAT ACC ATG AAA AGC AAC TTG GTA ATG CTT GAA AAT GGG AAA CAG CTG 480 Tyr Thr Met Lys Ser Asn Leu Val Met Leu Glu Asn Gly Lys Gln Leu 145 150 155 160
10	ACG GTT AAA AGA GAA GGA CTC TAT TAT GTC TAC ACT CAA GTC ACC TTC 528 Thr Val Lys Arg Glu Gly Leu Tyr Tyr Val Tyr Thr Gln Val Thr Phe 165 170 175
15	TGC TCT AAT CGG GAG CCT TCG AGT CAA CGC CCA TTC ATC GTC GGC CTC 576 Cys Ser Asn Arg Glu Pro Ser Ser Gln Arg Pro Phe Ile Val Gly Leu 180 185 190
20	TGG CTG AAG CCC AGC AGT GGA TCT GAG AGA ATC TTA CTC AAG GCG GCA 624 Trp Leu Lys Pro Ser Ser Gly Ser Glu Arg Ile Leu Leu Lys Ala Ala 195 200 205
25	AAT ACC CAC AGT TCC TCC CAG CTT TGC GAG CAG CAG TCT GTT CAC TTG 672 Asn Thr His Ser Ser Ser Gln Leu Cys Glu Gln Gln Ser Val His Leu 210 215 220
30	GGC GGA GTG TTT GAA TTA CAA GCT GGT GCT TCT GTG TTT GTC AAC GTG 720 Gly Gly Val Phe Glu Leu Gln Ala Gly Ala Ser Val Phe Val Asn Val 225 230 235 240
35	ACT GAA GCA AGC CAA GTG ATC CAC AGA GTT GGC TTC TCA TCT TTT GGC 768 Thr Glu Ala Ser Gln Val Ile His Arg Val Gly Phe Ser Ser Phe Gly 245 250 255
40	TTA CTC AAA CTC TGA 783 Leu Leu Lys Leu 260
45	(2) INFORMATION FOR SEQ ID NO:6:
50	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 260 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear
55	(ii) MOLECULE TYPE: protein
60	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
65	Met Ile Glu Thr Tyr Ser Gln Pro Ser Pro Arg Ser Val Ala Thr Gly 1 5 10 15
70	Leu Pro Ala Ser Met Lys Ile Phe Met Tyr Leu Leu Thr Val Phe Leu 20 25 30
75	Ile Thr Gln Met Ile Gly Ser Val Leu Phe Ala Val Tyr Leu His Arg 35 40 45
80	Arg Leu Asp Lys Val Glu Glu Glu Val Asn Leu His Glu Asp Phe Val 50 55 60
85	Phe Ile Lys Lys Leu Lys Arg Cys Asn Lys Gly Glu Gly Ser Leu Ser 65 70 75 80

27

Leu Leu Asn Cys Glu Glu Met Arg Arg Gln Phe Glu Asp Leu Val Lys
 85 90 95
 5 Asp Ile Thr Leu Asn Lys Glu Glu Lys Lys Glu Asn Ser Phe Glu Met
 100 105 110
 Gln Arg Gly Asp Glu Asp Pro Gln Ile Ala Ala His Val Val Ser Glu
 115 120 125
 10 Ala Asn Ser Asn Ala Ala Ser Val Leu Gln Trp Ala Lys Lys Gly Tyr
 130 135 140
 Tyr Thr Met Lys Ser Asn Leu Val Met Leu Glu Asn Gly Lys Gln Leu
 145 150 155 160
 15 Thr Val Lys Arg Glu Gly Leu Tyr Tyr Val Tyr Thr Gln Val Thr Phe
 165 170 175
 Cys Ser Asn Arg Glu Pro Ser Ser Gln Arg Pro Phe Ile Val Gly Leu
 180 185 190
 20 Trp Leu Lys Pro Ser Ser Gly Ser Glu Arg Ile Leu Leu Lys Ala Ala
 195 200 205
 Asn Thr His Ser Ser Ser Gln Leu Cys Glu Gln Gln Ser Val His Leu
 210 215 220
 Gly Gly Val Phe Glu Leu Gln Ala Gly Ala Ser Val Phe Val Asn Val
 225 230 235 240
 30 Thr Glu Ala Ser Gln Val Ile His Arg Val Gly Phe Ser Ser Phe Gly
 245 250 255
 Leu Leu Lys Leu
 35 260

(2) INFORMATION FOR SEQ ID NO:7:

- 40 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 689 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 45 (ii) MOLECULE TYPE: cDNA
 (iii) HYPOTHETICAL: NO
 50 (iv) ANTI-SENSE: NO
 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: CD27 ligand trimer (CD27L-3)
 55 (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 39..686
 60 (ix) FEATURE:
 (A) NAME/KEY: sig_peptide
 (B) LOCATION: 39..110

(ix) FEATURE:

(A) NAME/KEY: mat peptide

(B) LOCATION: 111..686

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

10	GGAAAACTCT CGAGGTACCT ATCCCGGGGA TCCCCACC ATG TTC CAT GTC TCT	53
	Met Phe His Val Ser	
	-24 -20	
15	TTT AGA TAT ATC TTT GGA ATT CCT CCA CTG ATC CTT GTT CTG CTG CCT	101
	Phe Arg Tyr Ile Phe Gly Ile Pro Pro Leu Ile Leu Val Leu Leu Pro	
	-15 -10 -5	
20	GTC ACT AGT TCT GAC CGT ATG AAA CAG ATA GAG GAT AAG ATC GAA GAG	149
	Val Thr Ser Ser Asp Arg Met Lys Gln Ile Glu Asp Lys Ile Glu Glu	
	1 5 10	
25	ATC CTA AGT AAG ATT TAT CAT ATA GAG AAT GAA ATC GCC CGT ATC AAA	197
	Ile Leu Ser Lys Ile Tyr His Ile Glu Asn Glu Ile Ala Arg Ile Lys	
	15 20 25	
30	AAG CTG ATT GGC GAG CGG ACT AGT CAG CGC TTC GCA CAG GCT CAG CAG	245
	Lys Leu Ile Gly Glu Arg Thr Ser Gln Arg Phe Ala Gln Ala Gln Gln	
	30 35 40 45	
35	CAG CTG CCG CTC GAG TCA CTT GGG TGG GAC GTA GCT GAG CTG CAG CTG	293
	Gln Leu Pro Leu Glu Ser Leu Gly Trp Asp Val Ala Glu Leu Gln Leu	
	50 55 60	
40	AAT CAC ACA GGA CCT CAG CAG GAC CCC AGG CTA TAC TGG CAG GGG GGC	341
	Asn His Thr Gly Pro Gln Gln Asp Pro Arg Leu Tyr Trp Gln Gly Gly	
	65 70 75	
45	CCA GCA CTG GGC CGC TCC TTC CTG CAT GGA CCA GAG CTG GAC AAG GGG	389
	Pro Ala Leu Gly Arg Ser Phe Leu His Gly Pro Glu Leu Asp Lys Gly	
	80 85 90	
50	CAG CTA CGT ATC CAT CGT GAT GGC ATC TAC ATG GTA CAC ATC CAG GTG	437
	Gln Leu Arg Ile His Arg Asp Gly Ile Tyr Met Val His Ile Gln Val	
	95 100 105	
55	ACG CTG GCC ATC TGC TCC TCC ACG ACG GCC TCC AGG CAC CAC CCC ACC	485
	Thr Leu Ala Ile Cys Ser Ser Thr Thr Ala Ser Arg His His Pro Thr	
	110 115 120 125	
60	ACC CTG GCC GTG GGA ATC TGC TCT CCC GCC TCC CGT AGC ATC AGC CTG	533
	Thr Leu Ala Val Gly Ile Cys Ser Pro Ala Ser Arg Ser Ile Ser Leu	
	130 135 140	
65	CTG CGT CTC AGC TTC CAC CAA GGT TGT ACC ATT GTC TCC CAG CGC CTG	581
	Leu Arg Leu Ser Phe His Gln Gly Cys Thr Ile Val Ser Gln Arg Leu	
	145 150 155	
70	ACG CCC CTG GCC CGA GGG GAC ACA CTC TGC ACC AAC CTC ACT GGG ACA	629
	Thr Pro Leu Ala Arg Gly Asp Thr Leu Cys Thr Asn Leu Thr Gly Thr	
	160 165 170	

29

CTT TTG CCT TCC CGA AAC ACT GAT GAG ACC TTC TTT GGA GTG CAG TGG 677
 Leu Leu Pro Ser Arg Asn Thr Asp Glu Thr Phe Phe Gly Val Gln Trp
 175 180 185

5 GTG CGC CCC TGA 689
 Val Arg Pro
 190

10 (2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 216 amino acids

(B) TYPE: amino acid

15 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

20 Met Phe His Val Ser Phe Arg Tyr Ile Phe Gly Ile Pro Pro Leu Ile
 -24 -20 -15 -10

25 Leu Val Leu Leu Pro Val Thr Ser Ser Asp Arg Met Lys Gln Ile Glu
 -5 1 5

Asp Lys Ile Glu Glu Ile Leu Ser Lys Ile Tyr His Ile Glu Asn Glu
 10 15 20

30 Ile Ala Arg Ile Lys Lys Leu Ile Gly Glu Arg Thr Ser Gln Arg Phe
 25 30 35 40

Ala Gln Ala Gln Gln Gln Leu Pro Leu Glu Ser Leu Gly Trp Asp Val
 45 50 55

35 Ala Glu Leu Gln Leu Asn His Thr Gly Pro Gln Gln Asp Pro Arg Leu
 60 65 70

40 Tyr Trp Gln Gly Gly Pro Ala Leu Gly Arg Ser Phe Leu His Gly Pro
 75 80 85

Glu Leu Asp Lys Gly Gln Leu Arg Ile His Arg Asp Gly Ile Tyr Met
 90 95 100

45 Val His Ile Gln Val Thr Leu Ala Ile Cys Ser Ser Thr Thr Ala Ser
 105 110 115 120

Arg His His Pro Thr Thr Leu Ala Val Gly Ile Cys Ser Pro Ala Ser
 125 130 135

50 Arg Ser Ile Ser Leu Leu Arg Leu Ser Phe His Gln Gly Cys Thr Ile
 140 145 150

55 Val Ser Gln Arg Leu Thr Pro Leu Ala Arg Gly Asp Thr Leu Cys Thr
 155 160 165

Asn Leu Thr Gly Thr Leu Leu Pro Ser Arg Asn Thr Asp Glu Thr Phe
 170 175 180

60 Phe Gly Val Gln Trp Val Arg Pro
 185 190

CLAIMS

What is claimed is:

1. A method of preparing a soluble, oligomeric mammalian protein by
5 culturing a host cell transformed or transfected with an expression vector encoding a fusion protein comprising a leucine zipper domain and a heterologous mammalian protein.
2. The method according to claim 1, wherein the heterologous mammalian protein comprises a transmembrane region of a membrane bound protein.
- 10 3. The method according to claim 2, wherein the leucine zipper domain comprises a peptide that trimerizes in solution.
4. The method according to claim 3, wherein the leucine zipper domain comprises amino acids 1 through 33 of SEQ ID NO:2.
5. The method according to claim 1, further comprising the steps of removing
15 the leucine zipper domain from the soluble, oligomeric mammalian protein.
6. The method according to claim 2, further comprising the steps of removing the leucine zipper domain from the soluble, oligomeric mammalian protein.
7. The method according to claim 3, further comprising the steps of removing the leucine zipper domain from the soluble, oligomeric mammalian protein.
- 20 8. The method according to claim 4, further comprising the steps of removing the leucine zipper domain from the soluble, oligomeric mammalian protein.
9. The method according to claim 1, wherein the heterologous mammalian protein comprises a globular mammalian protein.
10. The method according to claim 9, wherein the globular mammalian protein
25 is a cytokine.
11. A method of preparing a soluble, hetero-oligomeric mammalian protein by culturing a first host cell transformed or transfected with a first expression vector encoding a first fusion protein comprising a first leucine zipper domain and a first heterologous mammalian protein, culturing a second host cell transformed or
30 transfected with a second expression vector encoding a second fusion protein

comprising a second leucine zipper domain and a second heterologous mammalian protein, wherein the first and second leucine zipper domains preferentially form a hetero-oligomer, and combining the first and second fusion proteins under conditions promoting hetero-oligomer formation.

5 12. The method according to claim 11, wherein the first and second heterologous mammalian proteins comprise globular mammalian proteins.

 13. The method according to claim 12, wherein the globular mammalian proteins are cytokines.

 14. The method according to claim 11, wherein the first heterologous
10 mammalian protein comprises GM-CSF and the second heterologous mammalian protein comprises IL-3.

 15. The method according to claim 11, wherein the first and second heterologous mammalian proteins comprise extracellular regions of transmembrane proteins.

15 16. The method according to claim 15, wherein the extracellular regions are from different transmembrane proteins.

 17. The method according to claim 16, wherein the extracellular regions are from the same transmembrane protein.

 18. The method according to claim 1, wherein the fusion protein further
20 comprises a linker sequence.

 19. The method according to claim 11, wherein the fusion protein further comprises a linker sequence.




Figure 1B

Figure 1A




Figure 2

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/10034

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : C12N 15/12, 15/62

US CL : 435/69.7; 536/23.4

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.7, 172.3, 252.3, 320.1; 530/350; 536/23.4

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, STN/MEDLINE

search terms: GM-CSF, IL-3, fusion#, chimera?, hybrid#

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
<u>X</u> Y	The Journal of Immunology, Vol. 148, No. 5, issued 01 March 1992, Kostenly et.al., "FORMATION OF A BISPECIFIC ANTIBODY BY THE USE OF LEUCINE ZIPPERS", pages 1547 to 1553, see entire document.	<u>1,5,9,10</u> 2-4,6-8,11-19
Y	EP, A, 0 325 224 (Sledziewski et.al.) 26 July 1989, see entire document.	2-4,6-8,11-19
Y	US, A, 5,073,627 (Curtis et.al.) 17 December 1991, see entire document.	2-4,6-8,11-19



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be part of particular relevance	X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

12 JANUARY 1994

Date of mailing of the international search report

JAN 31 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

JOHN D. ULM

Facsimile No. NOT APPLICABLE

Telephone No. (703) 308-0196



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 15/12, 15/62	A1	(11) International Publication Number: WO 94/103 (43) International Publication Date: 11 May 1994 (11.05)
(21) International Application Number: PCT/US93/10034 (22) International Filing Date: 20 October 1993 (20.10.93) (30) Priority data: 07/969,703 23 October 1992 (23.10.92) US 08/107,353 13 August 1993 (13.08.93) US (71) Applicant: IMMUNEX CORPORATION [US/US]; 51 University Street, Seattle, WA 98101 (US). (72) Inventors: SPRIGGS, Melanie, K. ; 2256 12th Avenue West, Seattle, WA 98119 (US). SRINIVASAN, Subhashini ; 11325 N.E. 129th Street, Kirkland, WA 98034 (US). (74) Agent: PERKINS, Patricia, Anne; Immunex Corporation, 51 University Street, Seattle, WA 98101 (US).		(81) Designated States: AU, CA, JP, NZ, European patent (/ BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: METHODS OF PREPARING SOLUBLE, OLIGOMERIC PROTEINS (57) Abstract There is disclosed a method of preparing a soluble mammalian protein by culturing a host cell transformed or transfected with an expression vector encoding a fusion protein comprising a leucine zipper domain and a heterologous mammalian protein		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	CN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TC	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

TITLE

METHODS OF PREPARING SOLUBLE, OLIGOMERIC PROTEINS

5 TECHNICAL FIELD OF THE INVENTION

The present invention relates to a method of preparing soluble oligomeric proteins using recombinant DNA technology.

BACKGROUND OF THE INVENTION

10 The biological activity of proteins is dependent upon proper tertiary and quaternary structure, or conformation. Many proteins exists as oligomers (structures comprised of two or more polypeptide chains) in their native form. Such oligomers are often stabilized by non-covalent interactions, and are thus dependent on proper tertiary structure of the individual peptides. Expression of a recombinant protein in biologically
15 active form, exhibiting the proper tertiary and quaternary structure, by host cells which do not normally express a native form of the protein, frequently presents a significant challenge. Of particular interest in recombinant protein technology is expression of proteins that are membrane-bound in the biologically active form, as soluble proteins. Soluble proteins are useful as therapeutic agents, and in other applications requiring
20 large quantities of highly purified proteins.

Soluble forms of transmembrane proteins have been prepared by deleting the transmembrane and intracytoplasmic domains, and adding an appropriate signal peptide to enable secretion of the soluble form of the protein (Smith et al., *Science* 238:1704, 1987; Treiger et al., *J. Immunol.* 136:4099, 1986). Some soluble proteins have been
25 expressed as fusion proteins in which the extracellular domain of the membrane protein is joined to an immunoglobulin heavy chain constant region (Fanslow et al., *J. Immunol.* 149:65, 1992; Noelle et al., *Proc. Natl. Acad. Sci. U.S.A.* 89:6550, 1992), or with the extracellular domain of the murine T lymphocyte antigen CD8 (Hollenbaugh et al., *EMBO J.* 11:4313, 1992). However, such soluble proteins may not be
30 biologically active due to improper tertiary and/or quaternary structure. Some soluble forms of transmembrane proteins may be biologically active, but poorly expressed, or unstable under the conditions of expression or purification, due to changes in structure as a result of deletion of a portion or portions of the protein.

Leucine zipper is a term that is used to refer to a repetitive heptad motif
35 containing four to five leucine residues present as a conserved domain in several proteins. Leucine zippers fold as short, parallel coiled coils, and are believed to be responsible for oligomerization of the proteins of which they form a domain. Sequences derived from the *fos* and *jun* leucine zippers have been used in the formation

of bispecific antibodies by expression of DNA encoding the V_L and V_H regions of antibodies as fusion proteins with the leucine zipper sequences. (Kostelny et al., *J. Immunol.* 148:1547, 1992) Leucine zipper sequences have also been used to replace
5 the dimerization domain of λ repressor, a soluble DNA-binding protein of bacteriophage λ (Hu et al., *Science* 250:1400, 1990), and in the preparation of a dimeric form of MalE, a maltose binding protein of *E. coli* that is exported into the periplasmic space (Blondel and Bedoulle, *Protein Engineering* 4:457, 1991).

There is a need in the art to develop methods of expressing biologically active,
10 recombinant, oligomeric proteins, particularly soluble proteins that are membrane-bound in their biologically active configuration.

SUMMARY OF THE INVENTION

The present invention relates to a method of preparing a soluble, oligomeric
15 mammalian protein by culturing a host cell transformed or transfected with an expression vector encoding a fusion protein comprising a leucine zipper domain and a heterologous mammalian protein. In one embodiment, the heterologous mammalian protein comprises an extracellular domain of a mammalian transmembrane protein; the resulting fusion protein forms an oligomer. In another embodiment, the heterologous
20 mammalian protein comprises a soluble protein such as a cytokine; the resulting fusion protein forms an oligomer. In another embodiment, the leucine zipper domain is removed from the fusion protein, by cleavage with a specific proteolytic enzyme. In another embodiment, a hetero-oligomeric protein is prepared by utilizing leucine zipper
25 domains that preferentially form hetero-oligomers.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A illustrates the ability of soluble, oligomeric human CD40-L comprising a leucine zipper domain to stimulate the proliferation of human tonsillar B cells; Figure 1B illustrates the ability of soluble, oligomeric human CD40-L comprising
30 a leucine zipper domain to stimulate the proliferation of human peripheral blood B cells.

Figure 2 illustrates the inhibition of binding of CD27.Fc to MP.1 cells, which express CD27-L, by a soluble form of CD27-L, sCD27L-3, that comprises a leucine zipper domain. Curve 1 (---): $I=6.55$; $K=7.84e+11$; $K_a=2.93e+07$; $MF=8.84e-10$.
Curve 2 (—): $I=111.49$; $K=2.21e+08$; $K_a=2.93e+07$; $MF=8.83e-10$
35

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a method of preparing a soluble mammalian protein by culturing a host cell transformed or transfected with an expression vector encoding a fusion protein comprising a leucine zipper domain and a heterologous
40 mammalian protein. In one embodiment, the heterologous mammalian protein

comprises an extracellular domain of a mammalian transmembrane protein. Exemplary mammalian transmembrane proteins include members of the tumor necrosis factor/nerve growth factor receptor (TNFR/NGFR) family (Farrah and Smith, *Nature* 358:26, 1992; Goodwin et al., *Cell* 73:447, 1993), which includes CD40 Ligand (CD40-L), CD27 Ligand (CD27-L), OX40 Ligand (OX40-L), and TNF. Structural studies of certain members of this family of proteins indicate that they form homotrimers. The inventive method will also be useful for other members of this family.

Additionally, many other mammalian transmembrane proteins form oligomers, either hetero-oligomers or homo-oligomers, in their biologically-active form. Members of the hematopoietin receptor family (Cosman et al., *Trends Biochem. Sci.* 15:265; 1990) are exemplary of such proteins. Gearing et al. (*Science* 255:1434, 1992) reported the cloning of a gene encoding a protein (gp130) that conferred high-affinity binding to both leukemia-inhibitory factor (LIF) and Oncostatin M (OSM) when expressed in cells along with a low-affinity LIF receptor. Similar interactions of a low-affinity receptor and a second subunit protein, resulting in a high-affinity receptor have also been proposed for other members of this family (Hayashida et al., *Proc. Natl. Acad. Sci. U.S.A.* 87:0655, 1990; Kitamura et al., *Cell* 66:1165, 1991; Tavernier et al., *Cell* 66:1175, 1991; Devos et al., *EMBO J.* 10:2133, 1991). Soluble forms of the members of the hematopoietin receptor family will exhibit higher affinity for their cognate ligand when expressed as hetero-oligomers, or in some cases, as homo-oligomers. The same will be true for other transmembrane proteins that comprise two or more subunits.

In another embodiment, the heterologous mammalian protein comprises a soluble protein such as a cytokine; the resulting fusion protein forms an oligomer. Cytokines are soluble mediators released by cells during an immune or inflammatory response, which provide antigenically non-specific, intracellular signals that are crucial in regulating physiological processes. TNF α , TNF β and certain neurotrophins such as nerve growth factor (NGF) belong to the TNF/NGF family. Modeling studies of certain members of this family indicate that they are likely to form oligomers (Goh and Porter, *Protein Eng.* 4:385, 1991; Peitsch and Jongeneel, *Int. Immunol.* 5:233, 1993). Furthermore, other cytokines, including macrophage colony stimulating factor (M-CSF; Pandit et al., *Science* 258:1358, 1992) are also known to be oligomeric. Such cytokines will also be useful in the inventive method, wherein a leucine zipper domain stabilizes the proper quaternary structure of the oligomeric cytokine.

In another embodiment, hetero-oligomeric forms of cytokines are prepared. A fusion protein of granulocyte-macrophage colony stimulating factor (GM-CSF) and Interleukin-3 (IL-3) has been shown to be a more potent proliferation stimulus than

either factor alone or IL-3 and GM-CSF combined (U.S. Patents 5,073,627 and 5,108,910). Fusion proteins comprising GM-CSF and IL-3 and DNA sequences encoding such fusion proteins are described in U.S. Patents 5,073,627 and 5,108,910, respectively, both of which are incorporated by reference herein. A similar, bivalent
5 protein composed of GM-CSF and IL3 may be formed by the expression of these cytokines as fusion proteins comprising leucine zipper domains that preferentially form heterodimers.

In another embodiment, the leucine zipper domain is removed from the fusion protein, for example by cleavage with a specific proteolytic enzyme. In addition to a
10 leucine zipper sequence and a heterologous protein, such fusion proteins also comprise an amino acid sequence recognized, and cleaved, by a selected proteolytic enzyme. The leucine zipper domain functions to stabilize the recombinant fusion protein during expression and secretion. After purification of the secreted protein, the leucine zipper is enzymatically removed by treating with the proteolytic enzyme. The heterologous
15 protein may then become monomeric. Such monomeric forms of soluble proteins will be useful as receptor antagonists, for example, by binding to a cognate receptor and preventing signaling by preventing cross-linking of the receptor.

Leucine zipper domains

20 Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al., *Science* 240:1759, 1988). Leucine zipper domain is a term used to refer to a conserved peptide domain present in these (and other) proteins, which is responsible for dimerization of the proteins. The leucine zipper domain (also referred to herein as an oligomerizing, or oligomer-forming, domain) comprises a repetitive
25 heptad repeat, with four or five leucine residues interspersed with other amino acids. Examples of leucine zipper domains are those found in the yeast transcription factor GCN4 and a heat-stable DNA-binding protein found in rat liver (C/EBP; Landschulz et al., *Science* 243:1681, 1989). Two nuclear transforming proteins, *fos* and *jun*, also exhibit leucine zipper domains, as does the gene product of the murine proto-oncogene,
30 *c-myc* (Landschulz et al., *Science* 240:1759, 1988). The products of the nuclear oncogenes *fos* and *jun* comprise leucine zipper domains preferentially form a heterodimer (O'Shea et al., *Science* 245:646, 1989; Turner and Tjian, *Science* 243:1689, 1989). The leucine zipper domain is necessary for biological activity (DNA binding) in these proteins.

35 The fusogenic proteins of several different viruses, including paramyxovirus, coronavirus, measles virus and many retroviruses, also possess leucine zipper domains (Buckland and Wild, *Nature* 338:547, 1989; Britton, *Nature* 353:394, 1991; Delwart and Mosialos, *AIDS Research and Human Retroviruses* 6:703, 1990). The leucine

zipper domains in these fusogenic viral proteins are near the transmembrane region of the proteins; it has been suggested that the leucine zipper domains could contribute to the oligomeric structure of the fusogenic proteins. Oligomerization of fusogenic viral proteins is involved in fusion pore formation (Spruce et al, *Proc. Natl. Acad. Sci. U.S.A.* 88:3523, 1991). Leucine zipper domains have also been recently reported to play a role in oligomerization of heat-shock transcription factors (Rabindran et al., *Science* 259:230, 1993).

Leucine zipper domains fold as short, parallel coiled coils. (O'Shea et al., *Science* 254:539, 1991) The general architecture of the parallel coiled coil has been well characterized, with a "knobs-into-holes" packing as proposed by Crick in 1953 (*Acta Crystallogr.* 6:689). The dimer formed by a leucine zipper domain is stabilized by the heptad repeat, designated $(abcdefg)_n$ according to the notation of McLachlan and Stewart (*J. Mol. Biol.* 98:293, 1975), in which residues *a* and *d* are generally hydrophobic residues, with *d* being a leucine, which line up on the same face of a helix. Oppositely-charged residues commonly occur at positions *g* and *e*. Thus, in a parallel coiled coil formed from two helical leucine zipper domains, the "knobs" formed by the hydrophobic side chains of the first helix are packed into the "holes" formed between the side chains of the second helix.

The leucine residues at position *d* contribute large hydrophobic stabilization energies, and are important for dimer formation (Krystek et al., *Int. J. Peptide Res.* 38:229, 1991). Lovejoy et al. recently reported the synthesis of a triple-stranded α -helical bundle in which the helices run up-up-down (*Science* 259:1288, 1993). Their studies confirmed that hydrophobic stabilization energy provides the main driving force for the formation of coiled coils from helical monomers. These studies also indicate that electrostatic interactions contribute to the stoichiometry and geometry of coiled coils.

Several studies have indicated that conservative amino acids may be substituted for individual leucine residues with minimal decrease in the ability to dimerize; multiple changes, however, usually result in loss of this ability (Landschulz et al., *Science* 243:1681, 1989; Turner and Tjian, *Science* 243:1689, 1989; Hu et al., *Science* 250:1400, 1990). van Heekeren et al. reported that a number of different amino residues can be substituted for the leucine residues in the leucine zipper domain of GCN4, and further found that some GCN4 proteins containing two leucine substitutions were weakly active (*Nucl. Acids Res.* 20:3721, 1992). Mutation of the first and second heptadic leucines of the leucine zipper domain of the measles virus fusion protein (MVF) did not affect syncytium formation (a measure of virally-induced cell fusion); however, mutation of all four leucine residues prevented fusion completely

(Buckland et al., *J. Gen. Virol.* 73:1703, 1992). None of the mutations affected the ability of MVF to form a tetramer.

Recently, amino acid substitutions in the *a* and *d* residues of a synthetic peptide representing the GCN4 leucine zipper domain have been found to change the oligomerization properties of the leucine zipper domain (Alber, Sixth Symposium of the Protein Society, San Diego, CA). When all residues at position *a* are changed to isoleucine, the leucine zipper still forms a parallel dimer. When, in addition to this change, all leucine residues at position *d* are also changed to isoleucine, the resultant peptide spontaneously forms a trimeric parallel coiled coil in solution. Substituting all amino acids at position *d* with isoleucine and at position *a* with leucine results in a peptide that tetramerizes. Peptides containing these substitutions are still referred to as leucine zipper domains since the mechanism of oligomer formation is believed to be the same as that for traditional leucine zipper domains such as those described above. However, prior to the present invention, the effect of these substitutions upon longer peptides of which the leucine zipper is but a small domain was not known, nor was it known if peptides comprising these sequences could be expressed and secreted by cells.

Preparation of Gene Fragments and Oligonucleotides

Oligonucleotide fragments of about 12 to about 20 nucleotides may be prepared according to methods that are known in the art, for example, by using an automated DNA synthesizer. Several such fragments may be synthesized, which encode overlapping portions of a peptide, for example, a leucine zipper domain. Due to the degeneracy of the genetic code, most amino acids are encoded by two or more different nucleotide triplets. The selection of a triplet to encode a given amino acid will depend upon the organism in which the final gene product is to be expressed, among other considerations. Overlapping fragments may then be joined to form a DNA encoding a peptide of interest.

A polymerase chain reaction (PCR) technique (Saiki et al., *Science* 239:487, 1988) may be employed to amplify gene fragments encoding all or a portion of a protein of interest, using 5' (upstream) and 3' (downstream) oligonucleotide primers derived from the known DNA sequence of the gene, or a gene encoding a related protein. An exemplary set of PCR conditions includes: one cycle at 94°C for 2 minutes, followed by 42°C for two minutes; 30 cycles at 72°C for 1.5 minutes, followed by 94°C for one minute, then 48°C for 1 minute; and one cycle at 72°C for seven minutes. Restriction enzyme sites can also be added to the DNA sequences of interest, in order to facilitate ligation of the resulting PCR product with a plasmid or vector, or with an additional DNA sequence or sequences. Amplified DNA sequences

may be joined substantially as described by Yon and Fried (*Nucleic Acids Res.* 17:4895; 1989).

For example, as disclosed in U.S.S.N. 08/097,827, filed July 23, 1993, the disclosure of which is incorporated by reference herein, full length mouse OX40 was cloned using 5' (upstream) and 3' (downstream) oligonucleotide primers based on the published sequence of rat OX40. The upstream primer comprised a recognition site for the restriction endonuclease *Spe* I upstream of a sequence encoding the first six (N-terminal) amino acids of rat OX40. The downstream primer comprised a recognition site for the restriction endonuclease *Spe* I upstream of a sequence encoding the last five (C-terminal) amino acids of full-length OX40. The PCR product was digested with *Spe* I, and an approximately 800 bp fragment was isolated by gel filtration, and used in a second round of PCR reaction. The isolated fragment was ligated into *Spe* I cut plasmid, pBLUESCRIPT SK® (Stratagene Cloning Systems, La Jolla, CA), which had been treated with calf intestine alkaline phosphatase (CIAP) to prevent self-ligation.

In another example, a DNA encoding only the extracellular region of a transmembrane protein can be obtained by deleting DNA encoding the intracellular and transmembrane portions of the transmembrane protein. Methods to determine which residues should be deleted and for performing the actual deletions are well known in the art. For example, Smith et al. describe a soluble form of the human CD4 antigen prepared by deleting the transmembrane and intracellular portions of the CD4 antigen (*Science* 238:1704, 1987). Treiger et al. prepared a soluble form of an Interleukin-2 receptor using similar methods using similar methods (*J. Immunol.* 136:4099, 1986).

A fusion protein may be formed from an extracellular region and a protein (or portion thereof) that is known to be secreted. For example, soluble proteins comprising an extracellular domain from a membrane-bound protein and an immunoglobulin heavy chain constant region was described by Fanslow et al., *J. Immunol.* 149:65, 1992 and by Noelle et al., *Proc. Natl. Acad. Sci. U.S.A.* 89:6550, 1992. The extracellular domain of the murine T lymphocyte antigen CD8 has also be utilized to form soluble fusion proteins (Hollenbaugh et al., *EMBO J.* 11:4313, 1992).

Preparation of Fusion Proteins

Fusion proteins are polypeptides that comprise two or more regions derived from different, or heterologous, proteins or peptides. Fusion proteins are prepared using conventional techniques of enzyme cutting and ligation of fragments from desired sequences. PCR techniques employing synthetic oligonucleotides may be used to prepare and/or amplify the desired fragments. Overlapping synthetic oligonucleotides representing the desired sequences can also be used to prepare DNA constructs encoding fusion proteins. Fusion proteins can comprise several sequences, including a

leader (or signal peptide) sequence, linker sequence, a leucine zipper sequence, or other oligomer-forming sequences, and sequences encoding highly antigenic moieties that provide a means for facile purification or rapid detection of a fusion protein.

Signal peptides facilitate secretion of proteins from cells. An exemplary signal peptide is the amino terminal 25 amino acids of the leader sequence of murine interleukin-7 (IL-7; Namen et al., *Nature* 333:571; 1988). Other signal peptides may also be employed furthermore, certain nucleotides in the IL-7 leader sequence can be altered without altering the amino acid sequence. Additionally, amino acid changes that do not affect the ability of the IL-7 sequence to act as a leader sequence can be made.

The Flag[®] octapeptide (SEQ ID NO:1; Hopp et al., *Bio/Technology* 6:1204, 1988) does not alter the biological activity of fusion proteins, is highly antigenic and provides an epitope reversibly bound by a specific monoclonal antibody, enabling rapid detection and facile purification of the expressed fusion protein. The Flag[®] sequence is also specifically cleaved by bovine mucosal enterokinase at the residue immediately following the Asp-Lys pairing. Fusion proteins capped with this peptide may also be resistant to intracellular degradation in *E. coli*. A murine monoclonal antibody that binds the Flag[®] sequence has been deposited with the ATCC under accession number HB 9259; methods of using the antibody in purification of fusion proteins comprising the Flag[®] sequence are described in U.S. Patent 5,011,912, which is incorporated by reference herein.

A protein of interest may be linked directly to another protein to form a fusion protein; alternatively, the proteins may be separated by a distance sufficient to ensure that the proteins form proper secondary and tertiary structures. Suitable linker sequences (1) will adopt a flexible extended conformation, (2) will not exhibit a propensity for developing an ordered secondary structure which could interact with the functional domains of fusion proteins, and (3) will have minimal hydrophobic or charged character which could promote interaction with the functional protein domains. Typical surface amino acids in flexible protein regions include Gly, Asn and Ser. Virtually any permutation of amino acid sequences containing Gly, Asn and Ser would be expected to satisfy the above criteria for a linker sequence. Other near neutral amino acids, such as Thr and Ala, may also be used in the linker sequence. The length of the linker sequence may vary without significantly affecting the biological activity of the fusion protein. Linker sequences are unnecessary where the proteins being fused have non-essential N- or C-terminal amino acid regions which can be used to separate the functional domains and prevent steric interference. Exemplary linker sequences are described in U.S. patents 5,073,627 and 5,108,910, the disclosures of which are incorporated by reference herein.

When an oligomeric fusion protein is formed from the extracellular portion of a transmembrane protein, a DNA sequence encoding an oligomer-forming domain, such as a leucine zipper domain, is fused to a DNA sequence encoding the extracellular region of the transmembrane protein. The members of the fusion protein are joined such that the oligomer-forming domain of the fusion protein is located in the same orientation relative to the fusion protein as the transmembrane and intracytoplasmic regions of the native transmembrane protein. An oligomeric fusion protein will be stabilized by the coiled-coil interaction of leucine zipper domain. Thus, in one example, a fusion protein comprising an extracellular region derived from a ligand for CD40 (CD40-L), a type II transmembrane protein described in U.S.S.N. 07/969,703, the disclosure of which is incorporated by reference herein, the oligomer-forming domain, a leucine zipper sequence, is fused to the amino-proximal end of the extracellular region. In a fusion protein derived from a type I transmembrane protein, the oligomer-forming domain would be fused to the carboxy-proximal end of the extracellular region of the type I transmembrane protein. Other transmembrane proteins traverse the cell membrane more than once. Such transmembrane proteins will have two or more different extracellular regions. Soluble, oligomeric fusion proteins may also be prepared from two or more of such different extracellular regions from the same transmembrane protein.

Oligomeric forms of proteins that occur naturally in soluble form may also be prepared. In such cases, the oligomer-forming domain is joined to the soluble protein such that formation of an oligomer follows the conformation of the biologically active, soluble protein. Furthermore, either homo-oligomeric proteins or hetero-oligomeric proteins can be prepared, depending upon whether the oligomerizing domain(s) of the fusion protein preferentially form hetero-oligomers or homo-oligomers.

Expression Vectors

Recombinant expression vectors for expression of a fusion protein comprising an oligomer-forming domain and a heterologous mammalian protein by recombinant DNA techniques include a DNA sequence comprising a synthetic or cDNA-derived DNA fragment encoding an oligomer-forming domain, linked in frame to a DNA fragment encoding the heterologous protein. These DNA fragments are operably linked to suitable transcription and/or translational regulatory nucleotide sequences, such as those derived from a mammalian, microbial, viral, or insect gene. Examples of regulatory sequences include sequences having a regulatory role in gene expression (e.g., a transcription promoter or enhancer), an operator sequence to control transcription, a sequence encoding an mRNA ribosomal binding site, a polyadenylation site, splice donor and acceptor sites, and appropriate sequences which

control transcription, translation initiation and termination. In addition, sequences encoding signal peptides can be incorporated into expression vectors. For example, a DNA sequence for a signal peptide (secretory leader) may be operably linked to a DNA encoding a fusion protein comprising an oligomer-forming domain and a heterologous mammalian protein. The signal peptide is expressed as a part of a precursor amino acid sequence; the signal peptide enables improved extracellular secretion of translated fusion polypeptide by a yeast host cell.

Nucleotide sequences are operably linked when the regulatory sequence functionally relates to the DNA encoding the fusion protein. Thus, a promoter nucleotide sequence is operably linked to a DNA encoding a fusion protein if the promoter nucleotide sequence controls the transcription of the DNA encoding the fusion protein. Still further, a ribosome binding site may be operably linked to a sequence for a fusion protein if the ribosome binding site is positioned within the vector to encourage translation.

Transcription and translational control sequences for mammalian host cell expression vectors may be excised from viral genomes. For example, commonly used mammalian cell promoter sequences and enhancer sequences are derived from Polyoma virus, Adenovirus 2, Simian Virus 40 (SV40), and human cytomegalovirus. DNA sequences derived from the SV40 viral genome, for example, the SV40 origin, early and late promoters, enhancer, splice, and polyadenylation sites may be used to provide the other genetic elements required for expression of a structural gene sequence in a mammalian host cell. Viral early and late promoters are particularly useful because both are easily obtained from a viral genome as a fragment which may also contain a viral origin of replication (Fiers et al., *Nature* 273:113, 1978). Smaller or larger SV40 fragments may also be used, provided the approximately 250 bp sequence extending from the *Hind* III site toward the *Bgl* I site located in the SV40 viral origin of replication site is included.

Exemplary mammalian expression vectors can be constructed as disclosed by Okayama and Berg (*Mol. Cell. Biol.* 3:280, 1983). A useful high expression vector, PMLSV N1/N4, described by Cosman et al., *Nature* 312:768, 1984 has been deposited as ATCC 39890. Additional useful mammalian expression vectors are described in EP-A-0367566, and in U.S. Patent Application Serial No. 07/701,415, filed May 16, 1991, incorporated by reference herein. For expression of a type II protein extracellular region, such as OX40-L, a heterologous signal sequence may be added, such as the signal sequence for interleukin-7 (IL-7) described in United States Patent 4,965,195, or the signal sequence for interleukin-2 receptor described in United States Patent Application 06/626,667 filed on July 2, 1984. Another exemplary vector is

pDC406, which includes regulatory sequences derived from SV40, human immunodeficiency virus (HIV), and Epstein-Barr virus (EBV).

Expression vectors transfected into prokaryotic host cells generally comprise one or more phenotypic selectable markers. A phenotypic selectable marker is, for example, a gene encoding a protein that confers antibiotic resistance or that supplies an autotrophic requirement, and an origin of replication recognized by the host to ensure amplification within the host. Other useful expression vectors for prokaryotic host cells include a selectable marker of bacterial origin derived from commercially available plasmids. This selectable marker can comprise genetic elements of the cloning vector pBR322 (ATCC 37017). pBR322 contains genes for ampicillin and tetracycline resistance and thus provides simple means for identifying transformed cells. The pBR322 "backbone" sections are combined with an appropriate promoter and a OX40-L DNA sequence. Other commercially vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and pGEM1 (Promega Biotec, Madison, WI, USA).

Promoter sequences are commonly used for recombinant prokaryotic host cell expression vectors. Common promoter sequences include β -lactamase (penicillinase), lactose promoter system (Chang et al., *Nature* 275:615, 1978; and Goeddel et al., *Nature* 281:544, 1979), tryptophan (trp) promoter system (Goeddel et al., *Nucl. Acids Res.* 8:4057, 1980; and EP-A-36776) and tac promoter (Maniatis, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, p. 412, 1982). A particularly useful prokaryotic host cell expression system employs a phage λ P_L promoter and a cI857ts thermolabile repressor sequence. Plasmid vectors available from the American Type Culture Collection which incorporate derivatives of the λ P_L promoter include plasmid pHUB2 (resident in *E. coli* strain JMB9 (ATCC 37092)) and pPLc28 (resident in *E. coli* RR1 (ATCC 53082)).

Host Cells

Suitable host cells for expression of a fusion protein comprising an oligomer-forming domain and a heterologous mammalian protein include prokaryotes and yeast or higher eukaryotic cells. Prokaryotes include gram negative or gram positive organisms, for example, *E. coli* or *Bacilli*. Suitable prokaryotic host cells for transformation include, for example, *E. coli*, *Bacillus subtilis*, *Salmonella typhimurium*, and various other species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*. Higher eukaryotic cells include established cell lines of mammalian origin. Cell-free translation systems could also be employed to produce a fusion protein comprising an oligomer-forming domain and a heterologous mammalian protein using an RNA derived from DNA constructs disclosed herein.

In a prokaryotic host cell, such as *E. coli*, a fusion protein may include an N-terminal methionine residue to facilitate expression of the recombinant polypeptide in the prokaryotic host cell. The N-terminal Met may be cleaved from the expressed recombinant fusion protein. Prokaryotic host cells may be used for expression of fusion proteins that do not require extensive proteolytic or disulfide processing.

Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts are described, for example, in Pouwels et al. *Cloning Vectors: A Laboratory Manual*, Elsevier, New York, (1985). An expression vector carrying the recombinant fusion protein DNA is transfected or transformed into a substantially homogeneous culture of a suitable host microorganism or mammalian cell line according to methods that are known in the art, to form transfected or transformed host cells that express the fusion protein. Expressed fusion protein will be located within the host cell and/or secreted into culture supernatant fluid, depending upon the nature of the host cell and the gene construct inserted into the host cell.

A fusion protein comprising an oligomer-forming domain and a heterologous mammalian protein may be expressed in yeast host cells, preferably from the *Saccharomyces* genus (e.g., *S. cerevisiae*). Other genera of yeast, such as *Pichia* or *Kluyveromyces*, may also be employed. Yeast vectors will often contain an origin of replication sequence from a 2 μ yeast plasmid, an autonomously replicating sequence (ARS), a promoter region, sequences for polyadenylation, and sequences for transcription termination. Preferably, yeast vectors include an origin of replication sequence and selectable marker. Suitable promoter sequences for yeast vectors include promoters for metallothionein, 3-phosphoglycerate kinase (Hitzeman et al., *J. Biol. Chem.* 255:2073, 1980) or other glycolytic enzymes (Hess et al., *J. Adv. Enzyme Reg.* 7:149, 1968; and Holland et al., *Biochem.* 17:4900, 1978), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. Other suitable vectors and promoters for use in yeast expression are further described in Hitzeman, EPA-73,657.

Yeast vectors can be assembled, for example, using DNA sequences from pBR322 for selection and replication in *E. coli* (Amp^r gene and origin of replication). Other yeast DNA sequences that can be included in a yeast expression construct include a glucose-repressible ADH2 promoter and α -factor secretion leader. The ADH2 promoter has been described by Russell et al. (*J. Biol. Chem.* 258:2674, 1982) and Beier et al. (*Nature* 300:724, 1982). The yeast α -factor leader sequence directs secretion of heterologous polypeptides. The α -factor leader sequence is often inserted between the promoter sequence and the structural gene sequence. See, e.g., Kurjan et

al., *Cell* 30:933, 1982 and Bitter et al., *Proc. Natl. Acad. Sci. USA* 81:5330, 1984. Other leader sequences suitable for facilitating secretion of recombinant polypeptides from yeast hosts are known to those of skill in the art. A leader sequence may be modified near its 3' end to contain one or more restriction sites. This will facilitate fusion of the leader sequence to the structural gene.

Yeast transformation protocols are known to those of skill in the art. One such protocol is described by Hinnen et al., *Proc. Natl. Acad. Sci. USA* 75:1929, 1978. For example, one can select for Trp⁺ transformants in a selective medium, wherein the selective medium consists of 0.67% yeast nitrogen base, 0.5% casamino acids, 2% glucose, 10 µg/ml adenine and 20 µg/ml uracil. Yeast host cells transformed by vectors containing ADH2 promoter sequence may be grown for inducing expression in a "rich" medium. An example of a rich medium is one consisting of 1% yeast extract, 2% peptone, and 1% glucose supplemented with 80 µg/ml adenine and 80 µg/ml uracil. Derepression of the ADH2 promoter occurs when glucose is exhausted from the medium.

Mammalian or insect host cell culture systems could also be employed to express recombinant fusion protein. Examples of suitable mammalian host cell lines include the COS-7 line of monkey kidney cells (ATCC CRL 1651; Gluzman et al., *Cell* 23:175, 1981), L cells, C127 cells, 3T3 cells (ATCC CRL 163), Chinese hamster ovary (CHO) cells, HeLa cells, BHK (ATCC CRL 10) cell lines, and CV-1/EBNA cells (ATCC CRL 10478). The CV-1/EBNA cell line was derived by transfection of the CV-1 cell line with a gene encoding Epstein-Barr virus nuclear antigen-1 (EBNA-1) and constitutively express EBNA-1 driven from human CMV immediate-early enhancer/promoter. An EBNA-1 gene allows for episomal replication of expression vectors that contain the EBV origin of replication.

Protein Purification

Purified soluble fusion proteins are prepared by culturing suitable host/vector systems to express the recombinant soluble fusion proteins, which are then purified from culture media or cell extracts, using standard methods of protein purification that are optimized for each individual soluble fusion protein.

For example, supernatants from systems which secrete recombinant protein into culture media are clarified, and concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. Following the concentration step, the concentrate can be applied to a suitable purification matrix. Suitable matrices include those useful in affinity chromatography. For example, a suitable affinity matrix can comprise a cognate protein to which the

fusion proteins binds, or lectin or antibody molecule which binds the fusion protein, bound to a suitable support.

Alternatively, an ion exchange resin can be employed, for example, an anion exchange resin comprising a matrix or substrate having pendant diethylaminoethyl (DEAE) groups, or other suitable anion exchangers. The matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification. Alternatively, a cation exchange step can be employed. Suitable cation exchangers include various insoluble matrices comprising sulfopropyl or carboxymethyl groups.

One or more reversed-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify a soluble fusion protein. Size exclusion chromatography will also be useful in purifying soluble fusion proteins. Additionally, hydrophobic supports can also be used under low pressure conditions: an exemplary medium is phenyl-sepharose. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a homogeneous recombinant protein.

Biological Activity

Biological activity of recombinant, soluble fusion proteins is mediated by binding of the recombinant, soluble fusion protein to a cognate molecule. A cognate molecule is defined as a molecule which binds the recombinant soluble fusion protein in a non-covalent interaction based upon the proper conformation of the recombinant soluble fusion protein and the cognate molecule. For example, for a recombinant soluble fusion protein comprising an extracellular region of a receptor, the cognate molecule comprises a ligand which binds the extracellular region of the receptor. Conversely, for a recombinant soluble fusion protein comprising a ligand, the cognate molecule comprises a receptor (or binding protein) which binds the ligand.

Binding of a recombinant fusion protein to a cognate molecule is a marker for biological activity. Such binding activity may be determined, for example, by competition for binding to the binding domain of the cognate molecule (i.e. competitive binding assays). One configuration of a competitive binding assay for a recombinant soluble fusion protein comprising a ligand uses a radiolabeled, soluble receptor, and intact cells expressing a native form of the ligand. Such an assay is illustrated in Example 4 herein. Similarly, a competitive assay for a recombinant soluble fusion protein comprising a receptor uses a radiolabeled, soluble ligand, and intact cells expressing a native form of the receptor. Instead of intact cells expressing a native form of the cognate molecule, one could substitute purified cognate molecule bound to a solid phase. Competitive binding assays can be performed using standard

methodology. Qualitative or semi-quantitative results can be obtained by competitive autoradiographic plate binding assays, or fluorescence activated cell sorting, or Scatchard plots may be utilized to generate quantitative results.

Biological activity may also be measured using bioassays that are known in the art, such as a cell proliferation assay. Exemplary bioassays are described in Example 2 herein. The type of cell proliferation assay used will depend upon the recombinant soluble fusion protein. A bioassay for a recombinant soluble fusion protein that in its native form acts upon T cells will utilize purified T cells obtained by methods that are known in the art. Such bioassays include costimulation assays in which the purified T cells are incubated in the presence of the recombinant soluble fusion protein and a suboptimal level of a mitogen such as Con A or PHA. Similarly, purified B cells will be used for a recombinant soluble fusion protein that in its native form acts upon B cells. Other types of cells may also be selected based upon the cell type upon which the native form of the recombinant soluble fusion protein acts. Proliferation is determined by measuring the incorporation of a radiolabeled substance, such as ^3H thymidine, according to standard methods.

Yet another type assay for determining biological activity is induction of secretion of secondary molecules. For example, certain proteins induce secretion of cytokines by T cells. T cells are purified and stimulated with a recombinant soluble fusion protein under the conditions required to induce cytokine secretion (for example, in the presence of a comitogen). Induction of cytokine secretion is determined by bioassay, measuring the proliferation of a cytokine dependent cell line. Similarly, induction of immunoglobulin secretion is determined by measuring the amount of immunoglobulin secreted by purified B cells stimulated with a recombinant soluble fusion protein that acts on B cells in its native form, using a quantitative (or semi-quantitative) assay such as an enzyme immunoassay. Example 2 presents such assays.

The relevant disclosures of all references cited herein are specifically incorporated by reference. The following examples are offered by way of illustration, and not by way of limitation.

EXAMPLE 1

This example describes construction of a CD40-L DNA construct to express a soluble CD40-L fusion protein referred to as trimeric CD40-L. CD40-L is a type II transmembrane protein found on activated T cells, that acts as a ligand for the B cell antigen, CD40 (Armitage et al., *Nature* 357:80, 1992; Spriggs et al., *J. Exp. Med.* 176:1543, 1992). A gene encoding CD40-L has been cloned and sequenced as described in U.S.S.N. 07/969,703, filed October 23, 1992, the disclosure of which is incorporated by reference herein. CD40-L is a member of the Tumor Necrosis Factor

(TNF) family of proteins; several members of this family are believed to exist in trimeric form.

Trimeric CD40-L contains a leader sequence, a 33 amino acid sequence referred to as a "leucine zipper" (SEQ ID NO:2), and an eight amino acid hydrophilic sequence described by Hopp et al. (Hopp et al., *Bio/Technology* 6:1204, 1988; SEQ ID NO:1; referred to as Flag[®]), followed by the extracellular region of human CD40-L (amino acid 50 to amino acid 261 of SEQ ID NOs:3 and 4). The utility of the leader and the Flag[®] sequences have been described in previously. The 33 amino acid sequence presented in SEQ ID NO:2 trimerizes spontaneously in solution. Fusion proteins comprising this 33 amino acid sequence are thus expected to form trimers or multimers spontaneously.

The construct is prepared by synthesizing oligonucleotides representing a leader sequence, the 33 amino acid sequence described above (SEQ ID NO:2), and the Flag[®] sequence (SEQ ID NO:1), then ligating the final product to a DNA fragment encoding the extracellular region of human CD40-L (amino acids 50 to 261 of SEQ ID NOs:3 and 4).

The resulting ligation product in expression vector pDC406 was transfected into the monkey kidney cell line CV-1/EBNA (ATCC CRL 10478). The pDC406 plasmid includes regulatory sequences derived from SV40, human immunodeficiency virus (HIV), and Epstein-Barr virus (EBV). The CV-1/EBNA cell line was derived by transfection of the CV-1 cell line with a gene encoding Epstein-Barr virus nuclear antigen-1 (EBNA-1) that constitutively expresses EBNA-1 driven from the human CMV intermediate-early enhancer/promoter. The EBNA-1 gene allows for episomal replication of expression vectors, such as pDC406, that contain the EBV origin of replication.

Once cells expressing the fusion construct are identified, large scale cultures of transfected cells are grown to accumulate supernatant from cells expressing soluble, oligomeric CD40-L. The soluble, oligomeric CD40-L fusion protein in supernatant fluid is purified by affinity purification substantially as described in U.S. Patent 5,011,912. sCD40-L may also be purified using other protein purification methods, as described herein. Silver-stained SDS gels of the soluble, oligomeric CD40-L fusion protein can be prepared to determine purity. Similar methods are used to prepare and purify a trimer-forming construct comprising the extracellular region of murine CD40-L (amino acid 50 to amino acid 260 of SEQ ID NOs:5 and 6). Soluble CD40-L exhibits similar biological activity to that of membrane-bound CD40-L, as shown in Example 2.

Example 2

This example illustrates B cell proliferative activity and induction of polyclonal immunoglobulin secretion using soluble, oligomeric CD40-L prepared as described in Example 1. Human B cells were purified substantially as described in Armitage et al. (J. Immunol. 150:3671; 1993). Briefly, tonsillar tissue was gently teased and the resulting cell suspension centrifuged over Histopaque® (Sigma, St. Louis, MO). T cell-depleted preparations of cells (E^{-}) were obtained by removing T cells by rosetting with 2-aminoethylisothiuronium bromide-treated SRBC (sheep red blood cells) and treatment with B cell Lympho-kwik (One Lambda Inc., Los Angeles, CA) for 1 hour at 37°C to lyse contaminating non-B cells. Peripheral blood mononuclear cells (PBMC) were isolated in the same manner, with the additional step of treating the partially purified cells with 5 mM leucine methyl ester (Leu ME; Sigma, St. Louis, MO) in serum-free medium for one hour at room temperature prior to the Lympho-kwik step, to remove phagocytic cells.

B cell proliferation was measured with a 3H -thymidine incorporation assay, substantially as described in Armitage et al., *supra*. Cells were cultured for three days in the presence of soluble, oligomeric CD40-L, alone or in the presence of 5 ng/ml IL-4 (Immunex Corporation, Seattle, WA), 5 μ g/ml anti-IgM coated beads (BioRad, Richmond, CA), or a combination of IL-4 and anti-IgM. The results of a representative experiment to evaluate the ability of soluble, oligomeric CD40-L to induce B cell proliferation are shown in Figures 1A and 1B. sCD40-L induced proliferation of tonsillar B cells in the presence of IL-4, anti-IgM, or a combination of these to co-factors (Figure 1A). sCD40-L also induced proliferation of peripheral blood B cells in the presence of IL-4, anti-IgM, or a combination of these to co-factors, and with B cells obtained from some donors, a moderate level of proliferation in the absence of any co-factor (Figure 1B). These results parallel the results obtained with recombinant, membrane-bound CD40-L described in Armitage et al. *supra*.

Polyclonal immunoglobulin secretion was determined by isotype-specific ELISA on supernatant fluid from 10 day cultures of 1×10^5 B cells per well, substantially as described in Armitage et al., *supra*. Purified B cells were stimulated with a 1:20 dilution of supernatant fluid containing soluble, oligomeric CD40-L (sCD40-L), a 1:20 dilution of control supernatant (control S/N; conditioned medium from cells transfected with vector alone), or transfected CV-1/EBNA cells expressing membrane-bound CD40-L (CV1/CD40L; 3×10^4 cells/well), in the presence or absence of 10 ng/ml of either IL-2, IL-4 (both from Immunex Corporation, Seattle, WA) or IL-10 (Genzyme Corporation, Boston, MA). The results of a representative experiment measuring immunoglobulin secretion are presented in Table 1; values given represent

the quantity of each isotype secreted by the induced B cells in ng/ml, as measured by ELISA.

Table 1: Immunoglobulin Secretion Induced by CD40 Ligand

	Medium alone	Medium + IL-2	Medium + IL-4	Medium + IL-10	Isotype
Control S/N	114.9	424.5	69.4	132.2	IgM
sCD40L-3	212.3	2827.5	51.5	1726.5	
CV1/CD40L	91.8	1965.0	97.4	574.1	
Control S/N	16.2	161.0	40.1	22.7	IgG ₁
sCD40L-3	25.8	933.2	122.3	231.9	
CV1/CD40L	2.3	428.0	27.9	247.0	
Control S/N	45.1	44.2	39.6	50.0	IgA
sCD40L-3	56.7	248.0	48.7	353.9	
CV1/CD40L	64.7	513.8	34.7	447.2	
Control S/N	<0.3	<0.3	<0.3	<0.3	IgE
sCD40L-3	<0.3	<0.3	67.0	<0.3	
CV1/CD40L	<0.3	<0.3	77.6	<0.3	

5

These results indicated that soluble, oligomeric CD40-L induced polyclonal immunoglobulin secretion in the same manner as membrane-bound CD40-L. IL-2 and IL-10 enhanced secretion of IgM, IgG₁ and IgA; secretion of measurable amounts of IgE occurred only in the presence of IL-4, just as observed for membrane-bound CD40-L. The same pattern of immunoglobulin secretion was present when B cells from several different donors were tested, although the absolute quantities varied from donor to donor. In similar experiments in a murine system, a soluble, oligomeric construct of a murine CD40-L also gave comparable results to membrane-bound murine CD40-L.

15

Example 3

This example describes construction of a CD27-L DNA construct to express a soluble, oligomeric CD27-L fusion protein referred to as sCD27L-3. CD27-L is a type II transmembrane protein that binds to the lymphocyte antigen, CD27. CD27 is found on most peripheral blood T cells (Bigler et al., *J. Immunol.* 141:21, 1988; van Lier et al., *Eur. J. Immunol.* 18:811, 1988), and a subpopulation of B cells (Maurer et al., *Eur. J. Immunol.* 20:2679, 1990). CD27-L is a member of the tumor necrosis factor family of cytokines. A gene encoding CD27-L has been cloned and sequenced as

20

described in Goodwin et al., *Cell* 73:447 (1993), and in U.S.S.N. _____, filed _____, a continuation-in-part of U.S.S.N. 07/941,648, filed September 8, 1992, the disclosures of which are incorporated by reference herein.

5 The construct encoding sCD27L-3 contains a leader sequence, a 37 amino acid sequence comprising a leucine zipper domain, and the extracellular region of human CD27-L from amino acid 39 to amino acid 193; the nucleotide and amino acids sequences are presented in SEQ ID NOs:7 and 7. The construct was prepared by using methods that are well-known in the art to obtain a DNA encoding the extracellular region of CD27-L. Briefly, the extracellular region of CD27-L was amplified from a
10 full-length CD27-L cDNA using a PCR technique. The primers used were derived from the extracellular region of CD27-L (SEQ ID NO:7, nucleotides 222-245, for the 5' primer, and the complement of nucleotides 663-689 for the 3' primer) with addition of sequences encoding desired restriction enzyme sites (ACTAGT, which contains a *Spe* I site, for the 5' primer, and GCGGCCGC, which contains a *Not* I site, for the 3'
15 primer). The amplified PCR product, representing the extracellular domain of CD27-L, was cloned into an *Spe* I/*Not* I-cut SMAG (pDC206) vector. SMAG vector is a derivative of pDC201 (Sims et al., *Science* 241:585, 1988) that contains the murine IL-7 leader sequence. The vector was amplified, then cut with *Spe* I and treated with calf intestinal alkaline phosphatase. Oligonucleotides based on the amino acid sequence of a
20 leucine zipper (SEQ ID NO:1) were synthesized by standard methodology, and ligated with the *Spe* I-cut vector, to form an expression vector comprising a murine IL-7 leader sequence (Namen et al., *Nature* 333:571; 1988), a leucine zipper domain, and the extracellular domain of CD27-L. The expression vector was referred to as pDC206/sCD27L-3.

25 pDC206/sCD27L-3 was co-transfected into the monkey kidney cell line CV-1/EBNA (ATCC CRL 10478) along with a pSV3Neo plasmid. pSV3Neo (Mulligan and Berg, *Proc. Natl. Acad. Sci. U.S.A.* 78:2072; 1981) is a plasmid which expresses the SV40 T antigen, and thus allows for the episomal replication of the pDC206 plasmid.

30 Once cells expressing the fusion construct are identified, large scale cultures of transfected cells are grown to accumulate supernatant from cells expressing the soluble, oligomeric CD27-L fusion protein (referred to as sCD27L-3). sCD27L-3 in supernatant fluid is purified by affinity purification substantially as described in U.S. Patent 5,011,912. sCD27L-3 may also be purified using other protein purification
35 methods, as described herein. Silver-stained SDS gels of the soluble, oligomeric CD27-L fusion protein can be prepared to determine purity. sCD27L-3 binds to soluble CD27, and inhibits binding of soluble CD27 to cells expressing CD27-L, as described in Example 4.

Example 4

This example illustrates a binding inhibition activity of sCD27L-3. A soluble form of the human lymphocyte surface antigen CD27 was prepared substantially as described by Fanslow et al., *J. Immunol.* 149:65 (1992), to form a dimeric, Fc fusion construct referred to as CD27.Fc (Goodwin et al., *Cell* 73:447; 1993). CD27.Fc comprises the extracellular region of CD27 and an Fc region from a human IgG₁. sCD27L-3 inhibits binding of CD27.Fc to MP.1 cell, a human, Epstein-Barr virus-transformed B cell line that expresses endogenous CD27-L.

Conditioned supernatant fluid from CV-1/EBNA cells transfected with pDC206/sCD27L-3 was titrated in a 96 well plate. A constant amount of CD27.Fc (1 µg/well) was added to each well, followed by $1-2 \times 10^6$ MP.1 cells per well, in binding medium (RPMI-1640 containing 1 % bovine serum albumin, 0.2 % sodium azide and 20 mM HEPES, pH 7.2). The plate was incubated at 37°C for one hour. Cells were washed twice with PBS, then pelleted by centrifugation. ¹²⁵I-mouse anti-human IgG Fc was added to each well at a constant concentration, and the plate incubated for an additional hour at 37°C. The ¹²⁵I-mouse anti-human IgG Fc bound to the CD27.Fc that bound to the MP.1 cells. After the final incubation, cells were harvested over phthalate oil-containing tubes to separate the bound and free ¹²⁵I-mouse anti-human IgG Fc, and the amount of radioactivity quantitated using a gamma counter.

The results of this experiment are presented in Figure 2. sCD27L-3 exhibited a dose-dependent inhibition of the binding of CD27.Fc to MP.1 cells. By comparing the concentration at which the inhibition of binding of CD27.Fc is at 50% to the titration of inhibition by sCD27L-3, it was estimated that the concentration of sCD27L-3 in the conditioned medium was between 18 and 40 µg/ml. In making this comparison, the MW of sCD27L-3 was estimated to be 135 Kd (estimated MW of extracellular region of CD27-L was 45 Kd, multiplied by three for formation of trimer), and the binding of sCD27L-3 to CD27.Fc was assumed to occur at a molar ratio. The K_i was estimated to be 10 times the K_a , which was $3 \times 10^{-7} \text{M}^{-1}$, and the initial concentration was assumed to be $1 \times 10^{-8} \text{M}$. The results demonstrated that the initial assumption of a concentration of $1 \times 10^{-8} \text{M}$ was approximately 10-fold too low, and a 1:3 dilution of the supernatant fluid actually gave an estimated concentration of $1 \times 10^{-7} \text{M}$.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Spriggs, Melanie
Srinivasan, Subhashini

(ii) TITLE OF INVENTION: Methods of Preparing Soluble,
Oligomeric Proteins

(iii) NUMBER OF SEQUENCES: 8

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Immunex Corporation
(B) STREET: 51 University Street
(C) CITY: Seattle
(D) STATE: WA
(E) COUNTRY: USA
(F) ZIP: 98101

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Perkins, Patricia A
(B) REGISTRATION NUMBER: 34,693
(C) REFERENCE/DOCKET NUMBER: 1003

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (206)587-0430
(B) TELEFAX: (206)233-0644

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Asp Tyr Lys Asp Asp Asp Asp Lys
1 5

(2) INFORMATION FOR SEQ ID NO:2:

5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 33 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

15 Arg Met Lys Gln Ile Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys Ile
 1 5 10 15
 Tyr His Ile Glu Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly Glu
 20 20 25 30
 Arg

(2) INFORMATION FOR SEQ ID NO:3:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 786 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 30 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

35 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: Human
 40 (B) STRAIN: CD40-L

(ix) FEATURE:
 (A) NAME/KEY: CDS
 45 (B) LOCATION: 1..783

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

50 ATG ATC GAA ACA TAC AAC CAA ACT TCT CCC CGA TCT GCG GCC ACT GGA 48
 Met Ile Glu Thr Tyr Asn Gln Thr Ser Pro Arg Ser Ala Ala Thr Gly
 1 5 10 15
 CTG CCC ATC AGC ATG AAA ATT TTT ATG TAT TTA CTT ACT GTT TTT CTT 96
 Leu Pro Ile Ser Met Lys Ile Phe Met Tyr Leu Leu Thr Val Phe Leu
 55 20 25 30
 ATC ACC CAG ATG ATT GGG TCA GCA CTT TTT GCT GTG TAT CTT CAT AGA 144
 Ile Thr Gln Met Ile Gly Ser Ala Leu Phe Ala Val Tyr Leu His Arg
 60 35 40 45

	AGG TTG GAC AAG ATA GAA GAT GAA AGG AAT CTT CAT GAA GAT TTT GTA	192
	Arg Leu Asp Lys Ile Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val	
	50 55 60	
5	TTC ATG AAA ACG ATA CAG AGA TGC AAC ACA GGA GAA AGA TCC TTA TCC	240
	Phe Met Lys Thr Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser	
	65 70 75 80	
10	TTA CTG AAC TGT GAG GAG ATT AAA AGC CAG TTT GAA GGC TTT GTG AAG	288
	Leu Leu Asn Cys Glu Glu Ile Lys Ser Gln Phe Glu Gly Phe Val Lys	
	85 90 95	
15	GAT ATA ATG TTA AAC AAA GAG GAG ACG AAG AAA GAA AAC AGC TTT GAA	336
	Asp Ile Met Leu Asn Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu	
	100 105 110	
20	ATG CAA AAA GGT GAT CAG AAT CCT CAA ATT GCG GCA CAT GTC ATA AGT	384
	Met Gln Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser	
	115 120 125	
25	GAG GCC AGC AGT AAA ACA ACA TCT GTG TTA CAG TGG GCT GAA AAA GGA	432
	Glu Ala Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly	
	130 135 140	
30	TAC TAC ACC ATG AGC AAC AAC TTG GTA ACC CTG GAA AAT GGG AAA CAG	480
	Tyr Tyr Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln	
	145 150 155 160	
35	CTG ACC GTT AAA AGA CAA GGA CTC TAT TAT ATC TAT GCC CAA GTC ACC	528
	Leu Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr	
	165 170 175	
40	TTC TGT TCC AAT CGG GAA GCT TCG AGT CAA GCT CCA TTT ATA GCC AGC	576
	Phe Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser	
	180 185 190	
45	CTC TGC CTA AAG TCC CCC GGT AGA TTC GAG AGA ATC TTA CTC AGA GCT	624
	Leu Cys Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala	
	195 200 205	
50	GCA AAT ACC CAC AGT TCC GCC AAA CCT TGC GGG CAA CAA TCC ATT CAC	672
	Ala Asn Thr His Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His	
	210 215 220	
55	TTG GGA GGA GTA TTT GAA TTG CAA CCA GGT GCT TCG GTG TTT GTC AAT	720
	Leu Gly Gly Val Phe Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn	
	225 230 235 240	
55	GTG ACT GAT CCA AGC CAA GTG AGC CAT GGC ACT GGC TTC ACG TCC TTT	768
	Val Thr Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe	
	245 250 255	
55	GGC TTA CTC AAA CTC TGA	786
	Gly Leu Leu Lys Leu	
	260	

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

5

- (A) LENGTH: 261 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

Met Ile Glu Thr Tyr Asn Gln Thr Ser Pro Arg Ser Ala Ala Thr Gly
 1           5           10           15
15 Leu Pro Ile Ser Met Lys Ile Phe Met Tyr Leu Leu Thr Val Phe Leu
           20           25           30
Ile Thr Gln Met Ile Gly Ser Ala Leu Phe Ala Val Tyr Leu His Arg
           35           40           45
20 Arg Leu Asp Lys Ile Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val
           50           55           60
25 Phe Met Lys Thr Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser
           65           70           75           80
Leu Leu Asn Cys Glu Glu Ile Lys Ser Gln Phe Glu Gly Phe Val Lys
           85           90           95
30 Asp Ile Met Leu Asn Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu
           100          105          110
Met Gln Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser
           115          120          125
35 Glu Ala Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly
           130          135          140
Tyr Tyr Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln
40 145          150          155          160
Leu Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr
           165          170          175
45 Phe Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser
           180          185          190
Leu Cys Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala
           195          200          205
50 Ala Asn Thr His Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His
           210          215          220
Leu Gly Gly Val Phe Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn
55 225          230          235          240
Val Thr Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe
           245          250          255
60 Gly Leu Leu Lys Leu
           260

```

(2) INFORMATION FOR SEQ ID NO:5:

5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 783 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: cDNA to mRNA
 (iii) HYPOTHETICAL: NO
 (iv) ANTI-SENSE: NO

15 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: Mouse
 (B) STRAIN: CD40-L

20 (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 1..780

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATG	ATA	GAA	ACA	TAC	AGC	CAA	CCT	TCC	CCC	AGA	TCC	GTG	GCA	ACT	GGA	48
Met	Ile	Glu	Thr	Tyr	Ser	Gln	Pro	Ser	Pro	Arg	Ser	Val	Ala	Thr	Gly	
1				5					10					15		
CTT	CCA	GCG	AGC	ATG	AAG	ATT	TTT	ATG	TAT	TTA	CTT	ACT	GTT	TTC	CTT	96
Leu	Pro	Ala	Ser	Met	Lys	Ile	Phe	Met	Tyr	Leu	Leu	Thr	Val	Phe	Leu	
			20					25					30			
ATC	ACC	CAA	ATG	ATT	GGA	TCT	GTG	CTT	TTT	GCT	GTG	TAT	CTT	CAT	AGA	144
Ile	Thr	Gln	Met	Ile	Gly	Ser	Val	Leu	Phe	Ala	Val	Tyr	Leu	His	Arg	
		35					40					45				
AGA	TTG	GAT	AAG	GTC	GAA	GAG	GAA	GTA	AAC	CTT	CAT	GAA	GAT	TTT	GTA	192
Arg	Leu	Asp	Lys	Val	Glu	Glu	Glu	Val	Asn	Leu	His	Glu	Asp	Phe	Val	
	50					55					60					
TTC	ATA	AAA	AAG	CTA	AAG	AGA	TGC	AAC	AAA	GGA	GAA	GGA	TCT	TTA	TCC	240
Phe	Ile	Lys	Lys	Leu	Lys	Arg	Cys	Asn	Lys	Gly	Glu	Gly	Ser	Leu	Ser	
45	65				70				75					80		
TTG	CTG	AAC	TGT	GAG	GAG	ATG	AGA	AGG	CAA	TTT	GAA	GAC	CTT	GTC	AAG	288
Leu	Leu	Asn	Cys	Glu	Glu	Met	Arg	Arg	Gln	Phe	Glu	Asp	Leu	Val	Lys	
			85					90						95		
GAT	ATA	ACG	TTA	AAC	AAA	GAA	GAG	AAA	AAA	GAA	AAC	AGC	TTT	GAA	ATG	336
Asp	Ile	Thr	Leu	Asn	Lys	Glu	Glu	Lys	Lys	Glu	Asn	Ser	Phe	Glu	Met	
			100					105					110			
CAA	AGA	GGT	GAT	GAG	GAT	CCT	CAA	ATT	GCA	GCA	CAC	GTT	GTA	AGC	GAA	384
Gln	Arg	Gly	Asp	Glu	Asp	Pro	Gln	Ile	Ala	Ala	His	Val	Val	Ser	Glu	
		115					120					125				
GCC	AAC	AGT	AAT	GCA	GCA	TCC	GTT	CTA	CAG	TGG	GCC	AAG	AAA	GGA	TAT	432
Ala	Asn	Ser	Asn	Ala	Ala	Ser	Val	Leu	Gln	Trp	Ala	Lys	Lys	Gly	Tyr	
	130					135					140					

5 TAT ACC ATG AAA AGC AAC TTG GTA ATG CTT GAA AAT GGG AAA CAG CTG 480
 Tyr Thr Met Lys Ser Asn Leu Val Met Leu Glu Asn Gly Lys Gln Leu
 145 150 155 160
 ACG GTT AAA AGA GAA GGA CTC TAT TAT GTC TAC ACT CAA GTC ACC TTC 528
 Thr Val Lys Arg Glu Gly Leu Tyr Tyr Val Tyr Thr Gln Val Thr Phe
 165 170 175
 10 TGC TCT AAT CGG GAG CCT TCG AGT CAA CGC CCA TTC ATC GTC GGC CTC 576
 Cys Ser Asn Arg Glu Pro Ser Ser Gln Arg Pro Phe Ile Val Gly Leu
 180 185 190
 15 TGG CTG AAG CCC AGC AGT GGA TCT GAG AGA ATC TTA CTC AAG GCG GCA 624
 Trp Leu Lys Pro Ser Ser Gly Ser Glu Arg Ile Leu Leu Lys Ala Ala
 195 200 205
 20 AAT ACC CAC AGT TCC TCC CAG CTT TGC GAG CAG CAG TCT GTT CAC TTG 672
 Asn Thr His Ser Ser Ser Gln Leu Cys Glu Gln Gln Ser Val His Leu
 210 215 220
 GGC GGA GTG TTT GAA TTA CAA GCT GGT GCT TCT GTG TTT GTC AAC GTG 720
 Gly Gly Val Phe Glu Leu Gln Ala Gly Ala Ser Val Phe Val Asn Val
 225 230 235 240
 25 ACT GAA GCA AGC CAA GTG ATC CAC AGA GTT GGC TTC TCA TCT TTT GGC 768
 Thr Glu Ala Ser Gln Val Ile His Arg Val Gly Phe Ser Ser Phe Gly
 245 250 255
 30 TTA CTC AAA CTC TGA 783
 Leu Leu Lys Leu
 260

35 (2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 260 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: '

45 Met Ile Glu Thr Tyr Ser Gln Pro Ser Pro Arg Ser Val Ala Thr Gly
 1 5 10 15
 50 Leu Pro Ala Ser Met Lys Ile Phe Met Tyr Leu Leu Thr Val Phe Leu
 20 25 30
 Ile Thr Gln Met Ile Gly Ser Val Leu Phe Ala Val Tyr Leu His Arg
 35 40 45
 55 Arg Leu Asp Lys Val Glu Glu Glu Val Asn Leu His Glu Asp Phe Val
 50 55 60
 60 Phe Ile Lys Lys Leu Lys Arg Cys Asn Lys Gly Glu Gly Ser Leu Ser
 65 70 75 80

27

[illegible]

(2) INFORMATION FOR SEQ ID NO:7:

40 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 689 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

45 (ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

50 (iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: CD27 ligand trimer (CD27L-3)

55 (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 39..686

60 (ix) FEATURE:
 (A) NAME/KEY: sig_peptide
 (B) LOCATION: 39..110

29

CTT TTG CCT TCC CGA AAC ACT GAT GAG ACC TTC TTT GGA GTG CAG TGG 677
 Leu Leu Pro Ser Arg Asn Thr Asp Glu Thr Phe Phe Gly Val Gln Trp
 175 180 185

5 GTG CGC CCC TGA 689
 Val Arg Pro
 190

10 (2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 216 amino acids

(B) TYPE: amino acid

15 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

20 Met Phe His Val Ser Phe Arg Tyr Ile Phe Gly Ile Pro Pro Leu Ile
 -24 -20 -15 -10

25 Leu Val Leu Leu Pro Val Thr Ser Ser Asp Arg Met Lys Gln Ile Glu
 -5 1 5

Asp Lys Ile Glu Glu Ile Leu Ser Lys Ile Tyr His Ile Glu Asn Glu
 10 15 20

30 Ile Ala Arg Ile Lys Lys Leu Ile Gly Glu Arg Thr Ser Gln Arg Phe
 25 30 35 40

Ala Gln Ala Gln Gln Gln Leu Pro Leu Glu Ser Leu Gly Trp Asp Val
 35 45 50 55

Ala Glu Leu Gln Leu Asn His Thr Gly Pro Gln Gln Asp Pro Arg Leu
 60 65 70

40 Tyr Trp Gln Gly Gly Pro Ala Leu Gly Arg Ser Phe Leu His Gly Pro
 75 80 85

Glu Leu Asp Lys Gly Gln Leu Arg Ile His Arg Asp Gly Ile Tyr Met
 90 95 100

45 Val His Ile Gln Val Thr Leu Ala Ile Cys Ser Ser Thr Thr Ala Ser
 105 110 115 120

Arg His His Pro Thr Thr Leu Ala Val Gly Ile Cys Ser Pro Ala Ser
 125 130 135

50 Arg Ser Ile Ser Leu Leu Arg Leu Ser Phe His Gln Gly Cys Thr Ile
 140 145 150

55 Val Ser Gln Arg Leu Thr Pro Leu Ala Arg Gly Asp Thr Leu Cys Thr
 155 160 165

Asn Leu Thr Gly Thr Leu Leu Pro Ser Arg Asn Thr Asp Glu Thr Phe
 170 175 180

60 Phe Gly Val Gln Trp Val Arg Pro
 185 190

CLAIMS

What is claimed is:

1. A method of preparing a soluble, oligomeric mammalian protein by
5 culturing a host cell transformed or transfected with an expression vector encoding a fusion protein comprising a leucine zipper domain and a heterologous mammalian protein.
2. The method according to claim 1, wherein the heterologous mammalian protein comprises a transmembrane region of a membrane bound protein.
- 10 3. The method according to claim 2, wherein the leucine zipper domain comprises a peptide that trimerizes in solution.
4. The method according to claim 3, wherein the leucine zipper domain comprises amino acids 1 through 33 of SEQ ID NO:2.
- 15 5. The method according to claim 1, further comprising the steps of removing the leucine zipper domain from the soluble, oligomeric mammalian protein.
6. The method according to claim 2, further comprising the steps of removing the leucine zipper domain from the soluble, oligomeric mammalian protein.
7. The method according to claim 3, further comprising the steps of removing the leucine zipper domain from the soluble, oligomeric mammalian protein.
- 20 8. The method according to claim 4, further comprising the steps of removing the leucine zipper domain from the soluble, oligomeric mammalian protein.
9. The method according to claim 1, wherein the heterologous mammalian protein comprises a globular mammalian protein.
- 25 10. The method according to claim 9, wherein the globular mammalian protein is a cytokine.
11. A method of preparing a soluble, hetero-oligomeric mammalian protein by culturing a first host cell transformed or transfected with a first expression vector encoding a first fusion protein comprising a first leucine zipper domain and a first heterologous mammalian protein, culturing a second host cell transformed or
30 transfected with a second expression vector encoding a second fusion protein

comprising a second leucine zipper domain and a second heterologous mammalian protein, wherein the first and second leucine zipper domains preferentially form a hetero-oligomer, and combining the first and second fusion proteins under conditions promoting hetero-oligomer formation.

5 12. The method according to claim 11, wherein the first and second heterologous mammalian proteins comprise globular mammalian proteins.

13. The method according to claim 12, wherein the globular mammalian proteins are cytokines.

10 14. The method according to claim 11, wherein the first heterologous mammalian protein comprises GM-CSF and the second heterologous mammalian protein comprises IL-3.

15. The method according to claim 11, wherein the first and second heterologous mammalian proteins comprise extracellular regions of transmembrane proteins.

15 16. The method according to claim 15, wherein the extracellular regions are from different transmembrane proteins.

17. The method according to claim 16, wherein the extracellular regions are from the same transmembrane protein.

20 18. The method according to claim 1, wherein the fusion protein further comprises a linker sequence.

19. The method according to claim 11, wherein the fusion protein further comprises a linker sequence.

1/2




Figure 1B





Figure 1A



△ SMAG 4

○ CV1 HuCD27L III 7 Day

Figure 2

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/10034

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : C12N 15/12, 15/62

US CL : 435/69.7; 536/23.4

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.7, 172.3, 252.3, 320.1; 530/350; 536/23.4

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, STN/MEDLINE

search terms: GM-CSF, IL-3, fusion#, chimera?, hybrid#

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	The Journal of Immunology, Vol. 148, No. 5, issued 01 March 1992, Kostenly et.al., "FORMATION OF A BISPECIFIC ANTIBODY BY THE USE OF LEUCINE ZIPPERS", pages 1547 to 1553, see entire document.	<u>1,5,9,10</u> 2-4,6-8,11-19
Y	EP, A, 0 325 224 (Sledziewski et.al.) 26 July 1989, see entire document.	2-4,6-8,11-19
Y	US, A, 5,073,627 (Curtis et.al.) 17 December 1991, see entire document.	2-4,6-8,11-19

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be part of particular relevance	X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	&*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

12 JANUARY 1994

Date of mailing of the international search report

JAN 31 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

JOHN D. ULM

Facsimile No. NOT APPLICABLE

Telephone No. (703) 508-3196




Figure 1B





Figure 1A



Curve 1: I = 6.65 K = 7.84e+11 K_a = 2.93e+07 MF = 8.84e-10
 Curve 2: I = 111.49 K = 2.21e+08 K_a = 2.93e+07 MF = 8.83e-10

Figure 2